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Reactive oxygen species have received an increasing amount of attention over the past 
decade, not only due to their role in oxidative damage, but also because of their participation as 
second messengers on the relay of many signaling pathways and their role in the development of 
numeours fibrotic diseases. This Ph.D. dissertation focused on testing the hypothesis that ROS 
are necessary components of the EGF and PDGF pathways in leiomyoma and normal 
myometrial SMCs. The main findings of this work were: 1) leiomyoma smooth muscle cells 
(LSMCs) and myometrial smooth muscle cells (MSMCs) produce ROS in response to EGF and 
PDGF; 2) ROS are necessary for EGF- and PDGF-induced LSMCs and MSMCs proliferation, 
and sufficient to induce LSMCs proliferation; 3) ROS are necessary and sufficient to induce a 
fraction of Erk1/2 activation in LSMCs and MSMCs; 4) NADPH oxidase components are 
expressed in leiomyoma and normal myometrial tissue; 5) PDGF induces translocation of p47phox 
into lipid rafts in LSMCs; 6) PKC mediates Erk1/2 activation by PDGF in MSMCs and LSMCs; 
7) PKC activation alone is sufficient to induce ROS production in MSMCs and LSMCs; 8) 
hydrogen peroxide inhibits the activity of PTPases in LSMCs; 9) regulation of PTPase activity is 
important for myometrial and leiomyoma SMC proliferation. The findings suggest that ROS are 
necessary components of the EGF and PDGF pathways. There is also evidence that NADPH 
oxidase complex is the source of EGF and PDGF-induced ROS production, and that the 
mechanism of activation of this complex involves translocation of the subunit p47phox into lipid 
rafts as well as PKC activity. Furthermore, ROS might be acting by regulating protein tyrosine 
phosphatase enzymes, which in turn affect the proliferation of leiomyoma and myometrial 
SMCs. Based on the results obtained from my work I speculate that a subset of leiomyoma 
 iii 
tumors may originate from a growth advantage acquired by myometrial SMCs that overexpress 
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Uterine leiomyomas or fibroids are benign tumors of the reproductive tract that represent 
a significant public health and economic problem in the United States as well as worldwide. 
These tumors are characterized by abnormal growth of uterine smooth muscle cells and 
excessive production and deposition of extracellular matrix proteins, namely collagens type I and 
type III [1, 2]. Symptomatology include mainly pelvic pressure and/or pain, menorrhagia or 
hypermenorrhea, and infertility in some cases. Economical and social impacts come from the 
fact that it is estimated that approximately 70-80% of women will develop leiomyomas, with 
around 25% of symptomatic cases [3, 4]. 
A hypothesis formulated by our research group suggests that uterine leiomyomas may 
originate from a local injury to the uterine smooth muscle cells due to hypoxia or ischemia that 
occur during menstruation, as the spiral arteries of the myometrium constrict prior to the loss of 
the endometrium. This hypothesis is in agreement with some other well-established models such 
as the development of atherosclerosis plaques upon angioplasty/restenosis injury, and the 
development of liver fibrosis. These conditions share in common the mesenchymal origin of the 
normally quiescent cells and the phenotype switch into a more proliferative, myofibroblast-like 
cell type [5-8]. 
Recent studies have revealed that high levels of reactive oxygen species (ROS) is a 
common feature among several chronic disorders, some of which are fibrotic (Refer to 
APPENDIX A for a list of abbreviations). Pulmonary, hepatic, and cardiac fibrosis, 
atherosclerosis, type I diabetes, renal disorders, and a number of cancers are some of the illnesses 
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that have been associated with altered ROS production [9]. Although some studies have focused 
on the role of increased ROS levels in the context of oxidative stress and cell damage, I am 
interested in the role of ROS as a signaling molecule. Whether studies focus on oxidative stress 
or intracellular signaling, a significant portion of the literature supports the NADPH oxidase 
complex as the main source of ROS. For instance, this enzymatic complex is responsible for the 
release of ROS leading to cell growth and transformation [10, 11]. ROS production can affect the 
redox intracellular environment and ultimately influence the cell cycle [12, 13]. ROS can also 
regulate protein tyrosine phosphatases (PTPases) by oxidizing specific cysteine residues and 
rendering enzymes inactive [14-16]. In addition, NADPH oxidase-derived ROS is necessary for 
a variety of cellular events such as proliferation, migration, and transformation, in response to a 
variety of factors, e.g EGF, PDGF, insulin, angiotensin II [10, 11, 17-22].  
The overall goal of this work was to investigate the involvement of ROS in the EGF and 
PDGF proliferative pathways in myometrial and leiomyoma SMCs.  My overall hypothesis is 
that ROS are necessary for the proliferative pathways of the tested growth factors, and the 
scientific model I propose can be observed on Figure 1. Chapter 2 has an overview of the origin 
and regulation of SMC-specific gene expression, characteristics of leiomyoma tumors, 
description of the NADPH oxidase complex, and PTPases as targets of oxidation. Chapter 3 
shows experiments performed to accomplish specific aim 1 by determining the involvement of 
ROS as an intermediate in the PDGF proliferative pathway. Chapter 4 reports the 
characterization of the NADPH oxidase complex and its mechanism of activation in myometrial 
and leiomyoma SMCs, which is part of specific aim 2. Chapter 5 focuses on specific aim 3 in 
which ROS regulation of PTPases and the role of PTPases in proliferation of myometrial and 
leiomyoma SMCs were examined. 




2.1 MYOMETRIAL SMOOTH MUSCLE CELLS 
2.1.1 Origin  
Embryologically, smooth muscle cells (SMCs) originate from mesodermal or neural-crest 
mesenchymal cells. Smooth muscle cells from visceral organs, such as the uterus, derive from 
mesenchymal cells of splanchnic mesoderm origin, whereas smooth muscle in the head and neck 
region and vascular smooth muscle cells are derived mainly from neural-crest cells [23]. The 
development of the human uterus is due to proliferation of the mesenchymal cells present around 
the fused Mullerian ducts [24]. In a 16-day-old mouse, one can observe mesenchymal cells 
surrounding the Mullerian ducts [25] (figure 2). The adult uterus is composed of several layers of 
specific cell types. The innermost layer lining the uterine cavity is the epithelium, which along 
with the underlying stroma form the endometrium. A circular and a longitudinal layer of smooth 
muscle cells follow the endometrium respectively. Last, a single layer of cells, called the serosa, 
lines the outer side of the organ. Konishi (1984) observed by light microscopy that the uterus of a 
12-week gestation human fetus has sparse mesenchymal cells with no smooth muscle cells 
present. At 14 weeks the mesenchymal layer is divided into an inner and outer layer, whereas at 
18 weeks the first cells with some smooth muscle characteristics are observed. These are 
considered immature smooth muscle cells. At 40 weeks the outer layer is classified as the 
myometrium as the cells composing it express marked smooth muscle cell characteristics, 
whereas the inner layer corresponds to the uterine stroma [24]. Electron microscopy has 
confirmed the mesenchymal origin of uterine smooth muscle cells. Mesenchymal cells at 12 
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weeks contain few mitochondria, rough endoplasmic reticulum and free ribosomes with no 
evidence of cytoplasmic filaments or intracellular junctions, and only sparse collagen fibrils, 
indicative of an undifferentiated cell state. With progression of gestation, cells in the outer layer 
(prospective myometrium) acquire the morphological ultrastructure of smooth muscle cells such 
as abundant filaments with dense areas, numerous surface vesicles and external lamina [24]. 
Furthermore, at the junction between the myometrial layer and the endometrial stromal cells 
there are cells characterized as immature smooth muscle cells, suggestive of an area where cells 
are in a transitional state [24]. Brody et al. (1989) showed that in rats and mice there are 3 layers 
of mesenchymal cells: inner (adjacent to the epithelium), middle (prospective inner/circular 
myometrium) and outer. They also observed that early in myometrial development the outer and 
middle layers coexpress actin and vimentin, the latter being a marker for mesenchymal and 
fibroblastic cells [25]. Vimentin expression is repressed as smooth muscle cells differentiate, but 
remains present in cells that will compose the endometrial stromal [25]. These authors also 
reported that the cellular differentiation observed is accompanied by a change in cell orientation 
as stromal cells go from a radial to a random orientation whereas the inner myometrial layer 
becomes circular [25]. The interaction between epithelial and mesenchymal cells seems to be 
important for smooth muscle cell morphological differentiation as well as orientation as cells 
immediately adjacent to the epithelium become the endometrial stroma and cells further away 
become the circular and longitudinal myometrial cells. Furthermore, stromal cells immediately 
surrounding endometrial glands also acquire a circular orientation around the glandular epithelial 
cells [25]. Cunha et al. (1989) demonstrated that the endometrial epithelium is necessary and 
sufficient to induce differentiation of mesenchymal cells into smooth muscle cells [26]. By 
grafting uterine tissue under the kidney capsule of mice the authors observed that in grafts 
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containing both epithelium and mesenchyme, whether from intact uteri, digested uteri or tissue 
recombinants, mesenchymal cells formed bundles of actin-positive smooth muscle cells. There 
was no effect of the age of the epithelial cells on their ability to induce differentiation of 
mesenchymal cells [26]. On the other hand, grafts of mesenchymal cells alone were composed 
mainly of fibroblast cells, forming small amounts of smooth muscle cells mostly associated with 
blood vessels. More recently, Ono et al. (2007) identified a local source of uterine smooth 
muscle cells with stem cell-like characteristics [27]. These authors isolated a side population of 
the uterine myometrial cells, which were classified as immature smooth muscle cells due to low 
expression of several SMC markers. These cells were arrested in G0 phase with poor 
proliferation, however upon exposure to hypoxic conditions the cells proliferated efficiently and 
begun expressing smooth muscle cell markers such as α-smooth muscle actin and calponin. 
Furthermore, this human side population of myometrial cells was incorporated into mouse uteri 
following intra-uterine transplantation and underwent differentiation into smooth muscle cells. 
These cells also became activated during pregnancy as evidenced by oxytocin receptor 
expression. 
 
2.1.2 Molecular Control of Smooth Muscle Cell Gene Expression and Plasticity 
 The majority of the data regarding the molecular control of smooth muscle-specific gene 
expression has been generated using vascular smooth muscle cells as a model. Vascular smooth 
muscle cells have high plasticity and can reversibly switch phenotype according to 
environmental cues (e.g. conversion from a quiescent to a highly proliferative phenotype upon 
local injury). From what is known about uterine smooth muscle cells, mature, fully differentiated 
cells in the adult uterus are quiescent with very low proliferation rates. However, the highly 
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proliferative characteristic of uterine smooth muscle cells in leiomyoma tumors and their 
increased secretion of collagen, as well as the uterine growth in early pregnancy due to 
hyperplasia are suggestive of an ability of these cells to modulate their phenotype according to 
specific local conditions. 
 Although there are a number of smooth muscle cell markers such as smooth muscle (SM) 
α-actin, SM myosin heavy chain (SM-MHC), calponin, SM 22α, h-caldesmon, and smoothelin, 
most of them, with the exception of SM-MHC, are expressed at least transiently in other tissues 
in vivo [28]. Upon a phenotypic change these SM markers become downregulated. This 
differentiation pathway is regulated mainly at the transcriptional level. Some of the transcription 
factors involved are MADS box proteins (e.g. serum response factor-SRF), homeodomain 
proteins (e.g. HoxB7), kruppel-like zinc finger proteins (e.g. Sp1/3), GATA family 
(GATA4/5/6), helix-loop-helix (e.g. Twist), myocardin, Egr-1, AP-1, c-myb and others [28]. 
Serum response factor (SRF) is a transcription factor that was discovered as the factor 
activating transcription of c-fos in response to serum. It binds to the serum response element, 
called CArG box (CC[A/T]6GG), as a dimer and regulates the expression of many muscle-
specific genes. SRF is ubiquitously expressed, which suggests the necessity of other SM-specific 
regulatory mechanisms. There is evidence indicating that cofactors, posttranscriptional 
modifications of SRF, and altered SRF binding affinity to DNA are some of the mechanisms 
used to regulate SM-specific expression. A major finding in the field was the identification of a 
potent transcriptional cofactor, exclusively expressed in SMCs and cardiomyocytes, called 
myocardin [29]. Myocardin was first identified as a regulator of cardiac-specific gene expression 
and cardiac development, and has also been shown to activate SM-specific genes, without 
activating the SRF-responsive gene c-fos. 
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More recently chromatin modifications have also been reported as an important regulator 
of SM-specific gene expression. For instance, SRF binds preferentially to SM α-actin and SM-
MHC promoters in differentiated rather than undifferentiated cells, which coincides with higher 
acetylation levels in differentiated cells [30]. Moreover, the chromatin in promoters of SMC-
specific genes is more available for nuclease digestion in SMCs than in non-SMC [30]. These 
findings were strengthened by data showing the interaction of SRF with acetyltransferases such 
as CREB binding protein (CBP) and p300 and the synergistic activation of the SM MHC 
promoter by GATA6 and p300 interaction [30]. Furthermore, myocardin itself has a SAP domain 
with chromatin remodeling function [30]. In addition, platelet-derived growth factor BB (PDGF-
BB) is abundant at site of vascular injury as well as in leiomyoma tumors. It can reversibly 
repress SMC-specific genes inducing a switch in cell phenotype [30]. Interestingly, PDGF-BB 
treatment leads to competition for SRF between the transcription factors Elk and myocardin, by 
inducing nuclear translocation of Elk. It also induces expression of the histone deacetylase KLF4 
leading to deacetylation of histone H4 and reduction in SRF binding to SM-specific genes [30]. 
However growth-responsive genes retain high acetylation and have their transcription induced. 
McDonald and Owens (2007) created a model in which physiological chromatin of differentiated 
SMCs undergoes reorganization in response to events triggered by PDGF-BB and becomes 
transcriptionally repressive creating a pathological chromatin environment and leading to 
inhibition of SRF/myocardin complexes binding. The effects of PDGF-BB are reversible. In 
summary, PDGF-BB can inhibit the expression of SMC-specific genes in favor of the expression 
of growth responsive genes inducing a phenotypic switch from a contractile phenotype into a 
more proliferative one [30]. 
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2.2 UTERINE LEIOMYOMAS 
2.2.1 Classification, Epidemiology and Genetics 
Uterine leiomyomas, also called myomas, leiomyomata or fibroids, are benign tumors 
that arise from smooth muscle cells of the human myometrium. Leiomyomas are characterized 
by an increase in SMC proliferation and excessive deposition of extracellular matrix proteins 
primarily collagens type I and type III [1, 2, 31-33]. They can be classified as intramural (within 
the myometrium), submucosal (lying just beneath or within the endometrium), or subserosal 
(located just beneath the outer serosa) according to the spatial localization of these tumors in the 
uterine wall (Figure 3) [34]. Figures 4A and B show images of a normal size uterus with an 
intramural leiomyoma tumor and a uterus with two large subserosal leiomyoma tumors as well as 
some smaller intramural tumors, respectively. Epidemiological studies have shown that seven 
out of every ten Caucasian women and eight out of every ten African-American women will 
eventually develop uterine leiomyomas [3]. Whereas the estimated incidence indicates that the 
majority of women will be affected by this disorder, only 1 in every 4 women present with 
symptoms. These include pelvic pressure, abnormal uterine bleeding, and reproductive 
dysfunction. Figure 5A shows the distended abdomen of a woman carrying multiple leiomyoma 
tumors, which can be present at a variety of sizes and shapes (Figure 5B). Of women with 
employer-sponsored health insurance, age groups 35-44 and 45-54 represented 43.29% and 
45.65% of the clinically relevant leiomyoma cases, respectively, and of the 59.2% of women 
who had leiomyoma surgical treatment, more than 75% were hysterectomies [35]. Recent survey 
studies have reported that over 600,000 hysterectomies are performed in the United States every 
year, and that uterine leiomyomas represent 29.4% and 41.4% of the hysterectomies carried out 
in women ages 18-44 and 45-64, respectively [4]. The bleeding pattern in women with 
  9 
leiomyomas is characterized by menorrhagia or hypermenorrhoea, and can cause anemia as well 
as loss of work productivity and a sense of social stigmatization [32]. Alternative treatments for 
symptomatic leiomyoma tumors include less invasive surgeries such as myomectomy, uterine 
artery embolization, and endometrial ablation which preserve the uterus but may lead to 
reoccurrence. Non-surgical treatment involves the use of gonadotropin-releasing hormone 
(GnRH) agonists which effectively reduce tumor size but lead to bone density loss and 
resumption of tumor growth once treatment is terminated. This approach is a good option as a 
temporary treatment used prior to surgical removal of tumors to reduce tumor size. Recent 
studies by Hassan et al. (2009) using the Eker rat, which spontaneously develops leiomyoma 
tumors, tested the effectiveness of gene therapy as treatment for these tumors. The authors used 
adenovirus to deliver the herpes simplex virus 1 thymidine kinase gene to leiomyoma cells 
through intra-tumor injections. This procedure was followed by administration of ganciclovir, 
which is a target of simplex virus 1 thymidine kinase and upon phosphorylation becomes a toxic 
compound that leads to cellular apoptosis [36]. In a similar, study Hassan et al. (2008) delivered 
a dominant-negative estrogen receptor gene into leiomyoma tumors of Eker rats [37]. Both 
studies observed significant reductions in tumor size due to reduced proliferation and expression 
of proliferation-related genes as well as induction of apoptosis with no noticeable toxic effects, 
indicating that this technique may be a promising therapy for treatment of uterine leiomyomas. 
Ethnicity is a significant factor in the epidemiology of uterine leiomyomas. African 
American women having a 9.4 odds ratio having a tumor in the population analyzed by Faerstein 
et al. (2001), indicating that African American are more likely to develop these benign tumors 
than Caucasian women [38]. African Americans also are average 5.3 years younger at the time of 
uterine leiomyoma diagnosis and have more severe symptoms than Caucasian women [39]. 
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Other factors such as early menarche (<10 years old), high body mass index (BMI), diabetes, 
hypertension, and chlamydial infection are also positively correlated with higher risk of uterine 
leiomyomas, whereas use of oral contraceptive has been shown to have a negative influence on 
this condition [38, 40]. Pregnancy is a protective factor, with nulliparous women being an 
average 3 years younger at the age of diagnosis [39]. Other evidence for genetic predisposition 
comes from twin studies showing a strong correlation with women undergoing hysterectomy for 
leiomyomas [41], and studies showing that first-degree relatives of an affected woman were 
more likely to develop leiomyomas. However, these results may be biased, as a relative of a 
patient with leiomyomas might be more likely to seek diagnosis [42]. Studies using the X-linked 
glucose 6-phosphate dehydrogenase isozyme to determine clonality of leiomyomas have 
confirmed that these tumors are monoclonal in origin, meaning that a single SMC carrying a 
mutation that confers a growth advantage will give rise to the entire tumor cell population [43]. 
The monoclonal origin hypothesis was also confirmed by experiments testing the inactivation of 
X-linked phosphoglycerate-kinase [44]. Mutations in the fumarate hydratase gene, coding for a 
Kreb’s cycle enzyme, are associated with hereditary leiomyomatosis and renal cell cacinoma 
syndrome as well as Reed’s syndrome (Multiple Cutaneous and Uterine Leiomyomata). Both 
syndromes include cutaneous and uterine leiomyomas as well as a higher incidence of renal cell 
carcinoma and leiomyosarcoma, and they are now considered the same disease [45, 46]. 
Chromosomal abnormalities are present in 40-50% of leiomyoma tumors removed at surgery, 
with the most common ones being a translocation between chromosomes 12 and 14, deletion of 
chromosome 7, trisomy of chromosome 12, and rearrangements of 6p10q and 13q.  
Translocations between chromosomes 12 and 14 also occur in other mesenchymal solid tumors 
and involve HMGA2, a gene encoding a DNA binding protein that induces conformational 
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changes in DNA and may regulate transcription. Hodge et al. (2009) have reported a single TC 
repeat allele with 27 TC repeats located upstream of the transcription starting site in the 5’UTR  
of the HMGA2 gene to be associated with the presence of leiomyoma tumors, and tumors 
positive for the allele had slightly higher HMGA2 expression [47].  Moreover, rearrangement of 
chromosome 6 disrupts HMGA1 [48-50]. The diversity of genetic mechanisms potentially 
affecting leiomyoma development suggests that these benign tumors are composed of various, 
distinct subtypes of neoplasms, just as cancers are divided into numerous specific subsets of 
disorders [51]. Polymorphisms in genes like CYP17, cathechol-O-methyltransferase, and 
estrogen receptor, have all been associated with a higher risk of developing leiomyomas. The 
genotypes for the latter two genes, which were associated with higher risk of developing the 
tumors, show a higher frequency in African American women [52, 53]. 
 
2.2.2 Sex Steroid Hormones 
Although the mechanisms leading to the development of uterine leiomyomas remain to 
be determined, sex steroid hormones have been shown to play important roles in controlling 
tumor growth. The identification of steroid receptor expression in leiomyoma cells indicates a 
possible direct effect of these hormones on tumor growth. The cell proliferation rate is higher in 
leiomyoma than in normal myometrium regardless of the phase of the cycle but, when looking at 
the two different phases of the cycle, leiomyomas show a higher proliferative rate during the 
secretory phase during which progesterone is the dominant hormone [54, 55]. Estrogen receptors 
(ER) α and β and progesterone receptors (PR) A and B are upregulated at the mRNA and protein 
level in leiomyoma tissue compared to adjacent myometrium [55-58]. Treatment of leiomyoma 
SMCs with estrogen or progesterone increases cell proliferation [54, 59, 60], whereas use of 
  12 
respective antagonists blocks this effect [59, 60]. Leiomyomas have also been found to express 
the aromatase P450 enzyme suggesting the presence of an autocrine/paracrine system within 
leiomyomas by which the SMCs produce their own estradiol which stimulates growth 
independently of systemic sex steroid hormones [61, 62]. GnRH treatment causes suppression of 
the hypophyseal-gonadal axis, decreasing ovarian steroid levels and leading to tumor regression 
[63, 64]. Based upon the steroid-dependent characteristics of leiomyoma growth, therapy with 
either GnRH agonists or antagonists has been a successful alternative for treatment of uterine 
leiomyomas. A recent study by Hermon et al. (2008) showed the upregulation of ERα in 
leiomyoma compared to normal myometrium both in the secretory and proliferative phases [65]. 
Furthermore, this study also reported higher protein levels of phosphorylated ERα (phospho-
Ser118) in tumors versus normal tissue, with significantly higher levels in tumors at the 
proliferative phase in comparison to the secretory phase, suggesting higher responsiveness of 
tumor cells to estrogen. In addition, the above authors found higher levels of phospho-p44/42 
MAPK in leiomyoma tumors in the proliferative phase, with higher PCNA labeling in tumors in 
both phases of the menstrual cycle [65]. 
 
2.2.3 Growth Factors, Extracellular Matrix and MicroRNAs 
In addition to a direct effect on cell cycle and apoptosis regulation, sex steroid hormones 
also exert mitogenic effects through stimulation of growth factor production by their target cells.  
These in turn can act in an autocrine/paracrine fashion to modulate cell growth.  After detecting 
estrogen-stimulated increases in leiomyoma SMC proliferation, Barbarisi et al. (2001) observed 
that platelet-derived growth factor (PDGF) levels were increased in the conditioned medium 
from these cells and that this growth factor was responsible for the estrogen-induced mitogenic 
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effect on leiomyoma SMCs [60]. Furthermore, GnRH agonist therapy downregulates PDGF 
expression in women with leiomyomas and causes a reduction in tumor volume [66]. 
The expression of other growth factors such as epidermal growth factor (EGF), insulin-
like growth factor I (IGF-I), transforming growth factor beta 1 (TGF β1), basic fibroblast growth 
factor (bFGF) and heparin-binding EGF-like growth factor (HB-EGF), their respective receptors, 
and their regulation by estrogen and/or progesterone has been reported in leiomyomas [54, 59, 
67-71]. EGF is upregulated by progesterone during the luteal phase of the menstrual cycle in 
leiomyomas and EGF-R is upregulated by estrogen, whereas treatment of women with GnRH 
agonist reduced the binding of EGF to leiomyoma tissues versus leiomyomas from untreated 
patients [54, 72, 73]. Both EGF and PDGF stimulate proliferation of myometrial cells [74, 75]. 
HB-EGF, a member of the EGF family, has been shown to stimulate leiomyoma and myometrial 
cell proliferation and to inhibit apoptosis [68], however, these effects were more pronounced in 
myometrial cells, probably due to a higher expression of HB-EGF receptor (HER1) observed in 
those cells. 
The FGF receptor/ligand system, important for angiogenesis and induction of 
extracellular matrix (ECM) remodeling enzymes, also appears to play a role in the pathogenesis 
of leiomyomas as bFGF induces proliferation of both myometrial and leiomyoma SMCs.  
Expression of bFGF is stronger in leiomyoma tumors than in normal myometrium regardless of 
the phase of the cycle [70] and its expression is reduced during GnRH agonist treatment [76]. 
IGF-I is another growth factor implicated in the pathogenesis of leiomyomas. Both the 
expression of IGF-1 and its binding are increased by exposure to estrogen, and IGF-I seems to 
preferentially induce mitogenic activity in leiomyoma SMCs [67, 77]. The increase in cell 
number upon IGF-I treatment seems to be a result of its ability to promote proliferative activity 
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through upregulation of PCNA expression, and upregulation of Bcl-2, which inhibits apoptosis 
[78]. Recently, Yu et al. (2008) reported higher protein expression for EGF-R, ErbB4, FGFR1, 
FGFR2α, FGFR3, FGFR4, IR, IGF-IR, HGF-R, MSP-R, PDGF-Rα, PDGF-Rβ, SCF-R, Fit3, 
and M-CSF-R in leiomyoma tumors versus normal myometrium tissue [79]. These authors went 
further to study the IGF-I pathway and observed higher protein expression for IGF-I as well as 
higher levels of phosphorylation of downstream effectors of the IGF-I pathway such as IGF-IRβ, 
p44/42 MAPK and Shc in tumors compared to patient matched myometrium [79]. 
TGFβ is an important family of growth factors that play a significant role in the 
development of fibrotic conditions such as renal and hepatic fibrosis. Expression of TGF-β and 
TGF-β receptors has been confirmed in leiomyoma and myometrial SMCs, being more abundant 
in leiomyomas than in myometrium [80-82]. TGF-β 3 mRNA levels were increased during the 
luteal phase of the menstrual cycle, and treatment with the GnRH agonist leuprolide acetate 
caused a decrease in expression of TGF-β family members [83, 84]. Lee & Nowak (2001) also 
found that TGF-β3 inhibited DNA synthesis in myometrial SMCs, but stimulated it in 
leiomyoma cells [82]. Furthermore, inhibition of TGF-β caused a decrease in collagen I and III 
mRNAs in both myometrial and leiomyoma SMCs. Higher expression of TGF-β in leiomyomas 
and its role in stimulating increased synthesis of collagen correlates with the findings of Stewart 
et al. (1994), who observed a more intense immunostaining for collagen I and III in leiomyoma 
tissues [1]. This characteristic increase in collagen deposition in leiomyoma tumors was also 
observed by Leppert et al. (2004), who determined by electron microscopy that collagen fibrils in 
leiomyomas are very abundant and distributed in a disorganized fashion, as compared to fewer 
and well-aligned parallel fibrils in normal myometrium [33]. In addition to ECM protein 
production, processes associated with matrix turnover and remodeling are equally important, 
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being tightly regulated by matrix metalloproteinases (MMPs) and tissue inhibitor of MMPs 
(TIMPs). Dou et al. (1997) reported very low levels of MMP-1, -2 and -3 mRNA in leiomyomas 
compared to myometrium [85]. Another aspect related to the influence of the matrix composition 
to tumor growth is the level of glycosaminoglycans (GAGs). GAGs are present in the cellular 
and extracellular environment of tumors and can facilitate tumor cell migration, movement of 
molecules, and serve as a reservoir for growth factors and affect secretion of enzymes that 
degrade ECM. Wolanska et al. (1998) reported an increase in leiomyoma tissue content of 
sulphated GAGs during tumor growth [86]. 
Vasoactive agents (angiotensin II, serotonin), cytokines (tumor necrosis factor alpha - 
TNFα, interleukin 1 - IL-1), oleic acid, and thrombin also have been shown to play important 
roles in proliferation, migration and/or differentiation of cells of mesenchymal origin, either from 
the vascular system, rat leiomyoma cells (ELT-3), liver or in the kidney during development of 
fibrotic disorders [87-95]. 
More recently some studies have focused on the expression of microRNAs in leiomyoma 
tumors. Pan et al. (2008) identified a significant reduction in the number of microRNAs 
expressed in leiomyoma tissues compared to normal myometrial tissues. In addition, when 
comparing microRNA expression in myometrial tissue to leiomyoma tissue, myometrial SMCs, 
leiomyoma SMCs, immortalized leiomyoma SMCs and a leiomyosarcoma cell line there was a 
progressive decline in the number of microRNAs [96]. These findings suggest that microRNAs 
may play an important role in regulating the development of leiomyoma tumors. These authors 
also observed that the expression of miR-20a, miR-21 and miR-26a is responsive to ovarian 
steroids as tested in leiomyoma and myometrial SMCs by treatment with estradiol, medroxy 
progesterone acetate (MPA), estrogen receptor antagonist ICI-182780 and progesterone receptor 
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antagonist RU-486 [96]. Interestingly, qRT-PCR confirmed the expression pattern of numerous 
of microRNAs, several of which have as predicted targets a number of known important players 
in the pathogenesis of leiomyomas, such as TGFβ family members, EGR1 and 3, FGF familiy 
members, EGF, Bcl2, ESR1 and 2, PDGFA, IGF-I, VEGFB, PCNA, and enzymes related to 
steroid metabolism [96]. 
 
2.2.4 Atherosclerosis Model 
Atherosclerosis is a chronic consequence of obesity and diabetes, and results in 
thickening and hardening of the blood vessel walls (sclerosis), as well as loss of elasticity. The 
African American population has a high prevalence of hypertension (52% - >45 years old), and 
diabetes (12-15%), with 60% being over weight or obese [97]. African American women also 
have a higher prevalence of uterine leiomyomas and as the mechanism of atherosclerosis 
development is somewhat similar to the changes occurring during the formation of uterine 
leiomyomas. I will next review the results generated from research in vascular biology to try to 
gain insight in the mechanisms leading to the development of uterine leiomyomas. 
Hypertension, a symptom of cardiovascular disorders associated with atherosclerosis, is 
positively correlated with risk for uterine leiomyoma in premenopausal women [87]. 
Furthermore, angiotensin II, oleic acid, glucose and serotonin are found at elevated 
concentrations in hypertensive patients, and because these factors can also induce SMC 
proliferation and migration [90-92, 98-100], they have become targets of studies looking at their 
possible role in the pathology of cardiovascular disorders. 
Whereas the pathophysiology of uterine leiomyoma is unclear, these tumors are well 
characterized by increased growth of uterine SMCs and remodeling of the extracellular matrix 
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(ECM), particularly the abundant deposition of collagens I and III [1, 32, 33]. These processes 
are also present during the formation of atherosclerotic lesions, as described by Ross (1995) 
[101]. Both vascular smooth muscle cells (VSMCs) and UtSMCs undergo a phenotype change 
during the development of atherosclerosis and leiomyoma, respectively, mostly determined by 
matrix remodeling. Differentiated, non-proliferating cells are classified as the “contractile 
phenotype”. These cells express a series of proteins associated with contraction and are present 
in normal vasculature and myometrium. In atherosclerotic lesions, upon disruption of the basal 
membrane of blood vessels, some of these contractile proteins are downregulated, whereas ECM 
proteins, especially collagen I – III and fibronectin are upregulated. Under such conditions cells 
appear to dedifferentiate, assuming a “proliferative phenotype”, which also allows for cell 
migration. Shanahan & Weissberg (1998) identified several genes that are associated with the 
contractile (α-SM actin, γ-SM actin, calponin, SM myosin heavy chain, elastin, etc) versus 
proliferative (osteopontin and matrix gla protein) phenotypes [102]. Such phenotypic changes 
induced by different ECM proteins affect cell proliferation in vitro, as shown by Hirst et al. 
(2000), who observed that VSMC expressed lower levels of contractile markers (SM-MHC, 
calponin, SM-α-actin) when grown in fibronectin or collagen I, and had higher mitogen-induced 
proliferation rates than cells grown on laminin and Matrigel [5]. In addition, porcine VSMC 
showed a higher rate of proliferation in response to PDGF and bFGF when grown on fibronectin 
versus cells grown on laminin [103]. Given the influence of ECM on SMC phenotype, Blindt et 
al. (2002) decided to determine which integrins are important for cell-matrix interactions [104]. 
The authors found that SMCs grown on fibronectin expressed more integrin α5β1, and that 
inhibition of α5β1 was sufficient to inhibit migration, invasiveness, and attachment of SMCs to 
fibronectin. 
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Extrapolation of findings from development of vascular disorders to the development of 
leiomyomas gains further support when the pathophysiology of other fibrotic conditions is 
observed. Activation of stellate cells, mesenchymal cells present in the perivascular space in the 
liver, leads to the transformation of these cells from a quiescent cell into a myofibroblastic, 
proliferative and fibrogenic phenotype. This process is triggered by liver injury and results in 
changes in ECM composition. Fully activated stellate cells cause further ECM remodeling 
leading to scarring of the liver [6]. Interestingly, smooth muscle α-actin, a marker for smooth 
muscle cells, is also a marker for activated stellate cells [6]. Zeisberg et al. (2001) showed that 
inhibition of the basolateral assembly of collagen IV, an important component of basement 
membranes, caused epithelial-to-mesenchymal transdifferentiation of proximal tubular epithelial 
cells in renal fibrosis [7]. Such results reinforce the notion that this cell type is important in the 
developmental mechanisms of renal interstitial fibrosis, which include accumulation of 
fibroblasts and increased deposition of ECM components [7]. According to studies mentioned 
earlier in this chapter discussing the development of smooth muscle cells, they share some 
similarities with another important mesenchymal cell type with an important role in fibrosis, the 
stellate cells discussed above. Whether the SMCs present in leiomyoma tumors are 
dedifferentiated SMCs, recruited stem cells or originated from fully differentiated endothelial 
cells it is still unclear, because that can certainly depend on the kind of stimulus and the local 
microenvironment. However, the hypothesis of injury-induced phenotypic switch and abnormal 
proliferation has been proven in other fibrotic conditions and may be relevant for the 
pathogenesis of leiomyomas [8].  
In addition to the significant changes in ECM composition another acknowledged feature 
of these fibrotic disorders is a local increase in production of growth factors and expression of 
  19 
their receptors, accounting for an autocrine/paracrine regulation of further ECM deposition, cell 
proliferation and cell migration. Of particular interest to us is the mechanism by which growth 
factors, specifically EGF and PDGF lead to intracellular signal transduction ultimately causing 
these changes in gene expression. 
 
2.2.5 ROS and Signaling Pathways 
Regardless of the downstream molecules involved in the signaling pathway of EGF, 
PDGF, vasoactive factors and cytokines, most of them share a common feature upon binding to 
the respective receptor. An NADPH oxidase complex is activated to generate reactive oxygen 
species (ROS), mainly H2O2. Furthermore, ROS generation is necessary for downstream 
signaling leading to protein modifications, changes in gene expression, cell proliferation, 
migration, differentiation and tissue remodeling in a variety of cell types [10, 89, 91, 94, 99, 105-
120].  
ROS production through stimulation of NADPH oxidase is important for the proliferative 
and migratory response of SMCs to many factors. Nox1, a necessary component for NADPH 
oxidase activity in non-immune cells, shows increased mRNA and protein expression in vascular 
SMCs in response to PDGF [11], EGF [121], angiotensin II [109-111, 122], PGF2 α [123], and 
high glucose levels in diabetic mice [124].  Furthermore, treatment with angiotensin II [109-
111], EGF [115], PDGF [91], glucose [124], thrombin [105], and oleic acid [89] induces ROS 
production in vascular SMCs as well as in other cell types such as endothelial cells [106] and 
renal mesangial cells [107]. As upregulation of Nox1 gene expression and protein is associated 
with increased ROS production, and because Nox1 gene expression is also regulated by the 
above factors, it was postulated that ROS production could be an important step on the signaling 
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pathway of these factors. The use of ROS scavengers (catalase, superoxide dismutase, N-acetyl 
cysteine) and NADPH oxidase inhibitors (DPI) blocks the growth factor-induced increase in 
endothelial and SMCs proliferation and migration, indicating that these effects are indeed 
mediated by ROS production. Further studies on the mechanisms of action of ROS have 
confirmed their role as signaling molecules. H2O2, a more stable ROS and product of growth 
factor-induced NADPH oxidase activation, specifically reacts with thiolate anion (-S-), found 
only in cysteines located at a positively charged electrostatic field, allowing dissociation of the S- 
and stabilization of the structure. This reaction forms sulfenic acid as an intermediate, which is 
easily reduced, allowing for reversibility of the process. Both specificity and reversibility of the 
reaction are important characteristics of molecules involved in regulation of signaling pathways 
[125]. 
Much work has been done looking at the redox regulation of cell signaling, namely the 
influence of reducing or oxidizing agents on proteins involved in cell signaling. ROS generation 
has been primarily associated with increased phosphorylation and activity of ERK 1/2, p38 
MAPK, and/or JNK [89, 90, 93, 94, 98, 99, 108, 112, 114, 116, 120]. Antioxidants or NADPH 
oxidase inhibitors can block these effects and treatment with H2O2 can mimic them, although 
there is no evidence for direct interaction between ROS and these kinases. 
 Many fibrotic conditions such as pulmonary, hepatic and pancreatic fibrosis are 
associated with overproduction of ROS [9], therefore compounds that can inhibit specific 
NOX/DUOX family members represent potential therapeutic approaches for treatment of these 
chronic diseases [126]. ROS are strong candidates to be important in leiomyoma tumor 
development. Some work has been done on the characterization of the ROS generating system, 
ligand-dependent ROS generation, downstream targets of ROS action and cells’ responses to 
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increased and/or decreased ROS levels in other cell types. From these studies it appears that the 
parameters affected vary according to the specific cell type being studied. Thus there is no clear 
evidence as to the determining factors for ROS generation in leiomyoma SMCs and which 
molecules and pathways are activated by ROS in these cells. 
 
2.2.6 NADPH Oxidase: ROS-Generating System in Immune Cells 
NADPH oxidase is a membrane-associated enzyme complex that catalyzes the one-
electron reduction of oxygen to superoxide anion (O2-) using NADPH as a substrate. Superoxide 
is then further dismuted to hydrogen peroxide (H2O2), as well as other reactive oxygen species 
(ROS) that are used as microbicidals for host defense [127]. The NADPH oxidase complex was 
first characterized in immune cells where it can be activated by antigens and inflammatory 
mediators. The complex is composed of five subunits: gp91phox, p22phox, p47phox, p67phox, and 
p40phox, where phox stands for phagocytic oxidase. Gp91phox is a transmembrane protein, and its 
C-terminal region can interact with cytosolic components during enzyme activation [127]. 
P22phox is another transmembrane protein, with intra and extracellular portions. It interacts with 
gp91phox to form cytochrome b558 (cytb). Dissociation of the cytb complex causes enzyme 
inactivity. P47phox and p67phox are cytosolic proteins containing two SH3 domains important for 
interaction with other proteins. These proteins can be found in a free form or in a complex. 
NADPH oxidase can be activated in a receptor-mediated or receptor independent manner. In 
immune cells receptor mediated stimuli are chemotactic tripeptide N-formyl-Met-Ley-Phe 
(FMLP) and immune complexes, and receptor independent stimuli are long-chain unsaturated 
fatty acids and phorbol 12-myristate 13-acetate (PMA). These stimuli ultimately lead to 
phosphorylation of p47phox, which binds to p67phox and the complex is then translocated to the 
  22 
cell membrane, where these two interact with cytb to form activated NADPH oxidase. P40phox is 
40kDa protein and the last member of the NADPH oxidase complex identified in bone marrow 
cells such as neutrophils, mast cells, B and T cells, monocytes and basophils. It is found 
associated with p47phox and p67phox in a complex [128]. 
 
2.2.7 NADPH Enzyme Complex Activation 
As inhibitors of phosphorylation prevented NADPH oxidase activation in cell free 
systems, it was hypothesized that at least one of the enzyme complex components has to be 
phosphorylated to allow for enzyme activity. Ago et al. (1999) showed in a cell-free as well as 
whole-cell system that p47phox has 3 amino acids that undergo conformational changes upon 
phosphorylation, thus becoming exposed and allowing for interaction with p22phox on the cell 
membrane (Figure 6) [129]. p47phox is thought to act only as a link between p67phox and the 
cytochrome b558, because in a free cell system p47phox is not necessary for enzyme activity, 
while p67phox is important for the transfer of electrons from NADPH to the flavincytochrome 
b558 [127, 130]. In some cell types phospholipase C (PLC), phosphoinositide-3 kinase (PI3K) 
and protein kinase C (PKC) are upstream mediators of NADPH oxidase complex activation [89, 
113, 118, 119, 131]. 
Guanine nucleotide-binding proteins (GTPase) are necessary components for NADPH 
oxidase activation and ROS production. Rac2 is important for NADPH oxidase activation in 
phagocytes [130, 132], while in non-phagocytic cells Rac1 seems to be important instead [133]. 
Rac GTPase exchanges GTP for GDP and becomes active, being targeted to the cell membrane. 
Quinn et al. (1993) have shown that Rac is translocated to the cell membrane in response to both 
receptor and non-receptor stimulation of NADPH oxidase and its translocation kinetics was 
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parallel to p47phox/p67phox translocation and superoxide production, indicating a possible 
participation of Rac during complex activation [132]. Further evidence for the role of Rac during 
NADPH oxidase activation comes from studies showing that GTP-bound Rac contains a domain, 
called Switch I, which undergoes conformational changes that are important for Rac interaction 
with p67phox and consequently, for NADPH oxidase activity [130] Chanock [127]. 
Although in endothelial cells the NADPH oxidase complex exists as a preassembled 
intracellular complex [134], in VSMCs the complex seems to function more similarly to the way 
it does in phagocytes, with membrane subunits and cytosolic subunits that need to be 
translocated to the cell membrane making the complex active upon stimulation [110]. Cheng & 
Lambeth (2004) indicated that cells co-transfected with Nox1, Noxo1 and Noxa1 display 
constitutive ROS production regardless of the presence of a stimulus, as Noxo1 co-localizes with 
Nox1 on the membrane of resting cells bound to phosphatidylinositol lipids [135]. Mutations in 
the PX domain of Noxo1, which mediates its interaction with the cell membrane, lead to a 
decrease in its lipid binding and Nox1 activation with consequent lower ROS production. Such 
results indicate that the mechanism by which ROS are produced might depend on the NADPH 
oxidase subunit homologues being expressed in specific cell types and their combination to form 
the active complex as well as their own specific characteristics. For example, in cells in which 
p47phox is among the subunits responsible for the NADPH oxidase complex activity, p47phox 
needs to be phosphorylated in order to be targeted to the membrane. However, if Noxo1 is 
required instead, the NADPH oxidase complex is usually found preassembled and constantly 
active. Furthermore, c-Src kinase has been shown to be necessary for NADPH oxidase activation 
in one study [110], but only a downstream target of ROS in another [91]. Even the MAP kinases 
that are affected by ROS generation vary according to the cell type studied. 
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2.2.8 NADPH Oxidase in Non-Immune Cells 
In addition to the generation of ROS as a defense mechanism by immune cells, ROS are 
also thought to be an undesirable product of oxygen metabolism that, by being highly reactive, 
can cause uncontrolled protein and DNA modifications. Studies showing that non-immune cells 
are able to generate ROS in response to growth factors, hormones, and lipids raised the question 
whether ROS, released in a controlled manner, could be signaling molecules necessary for the 
intracellular relay of extracellular signals. The ability of NADPH oxidase inhibitors to block 
ROS generation in non-immune cells suggests the presence of a NADPH oxidase-like ROS 
generating system in these cells. When looking for the components of the NADPH oxidase 
complex, non-phagocytic cells were still able to generate similar amounts of ROS compared to 
normal cells even though they lacked the gp91phox subunit, a necessary component for ROS 
production in phagocytic cells. Such results are indicative that homologues of this subunit could 
be present in non-phagocytic cells [136, 137]. In fact, the laboratory of Dr David Lambeth was 
the first group to identify a homolog of human gp91phox, initially called Mox1, and now officially 
termed Nox1 (NADPH oxidase) [11]. Subsequently, his lab also cloned and sequenced three new 
homologues of gp91phox, called Nox3, Nox4 and Nox5 and assessed their expression in different 
cell types [137] (Figure 7). 
Gp91phox homologues in non-immune cells (Figure 8) are classified in three subgroups. 
The first is the gp91phox sub-family, consists of gp91phox (neutrophils, macrophages), nox1 
(colon, VSMCs, prostate), nox3 (fetal kidney, fetal liver, fetal lung, fetal spleen) and nox4 
(kidney, osteoclasts, pancreas, placenta, skeletal muscle, ovary, astrocytes), all approximately 
65kD in size and very similar in conformation to gp91phox. Duox1 (thyroid, lung) and duox2 
(thyroid, colon) are approximately three times larger than gp91phox (≈ 180kD) and form the Duox 
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sub-family, which contains two extra domains, an N-terminal peroxidase homology domain and 
a central domain with two EF-hand calcium-binding motifs. The Nox5 subgroup has a short 
splice variant (fetal kidney) similar to gp91phox in size, or a long variant (spleen, testis) 
containing a calcium-binding domain [136-140]. 
The cytosolic subunits p47phox and p67phox have also been found to have homologues in 
non-phagocytic cells. The p47phox homolog is a 41kD protein called Nox organizer 1 (Noxo1), 
and the p67phox homolog is a 51kD protein called Nox activator 1 (Noxa1). Both novel subunits 
support ROS production and respond more efficiently in cells containing the non-phagocytic 
catalytic subunit of the NADPH oxidase complex, Nox1 [141, 142] (Figure 9). Noxo1 has a 27% 
sequence identity (percentage of identical amino acid residues), a 46% sequence similarity 
(percentage of amino acid residues with similar properties) and a high structural similarity 
(similarities in size and conserved domain structure) to p47phox. Despite these similarities Noxo1 
lacks serine residues on the C-terminal region. These serine residues are present on p47phox and 
account for an auto-inhibitory domain. When phosphorylated, C-terminal serine residues allow 
interaction of p47phox with the NADPH complex. A PXXP motif, also present in the PX domain 
of p47phox and important for intra-molecular interaction with the protein C-terminal SH3 
domains, is also lacking in Noxo1. Noxa1 is also very similar to its phox homolog, p67phox, with 
38% sequence identity and 56% sequence similarity. The only structural difference between the 
two is the lack of a central SH3 domain in Noxa1 [141]. 
 
2.2.9 Protein Tyrosine Phosphatases (PTPases) 
Inhibition of phosphatase activity is an important process for the tight regulation of 
signaling pathways, as control over the sequential steps during the signal relay is obtained 
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mainly through phosphorylation and dephosphorylation of proteins by kinases and phosphatases, 
respectively. Protein tyrosine phosphatases (PTPases) are known targets of ROS action and 
could account for the effects of ROS generation on MAPK phosphorylation and activation. This 
specific family of phosphatases is characterized by a motif containing a cysteine residue that 
resides in a unique environment providing the cysteine with a very low pKa. This feature 
enhances its nucleophilic properties but also makes it susceptible to oxidation [15]. Very detailed 
work on H2O2 inhibition of PTPase was done by Denu & Tanner (1998), who showed that H2O2 
action is specific to PTPase, not inhibiting serine/threonine phosphatases (PP) [143]. The authors 
also showed that PTPase inactivation was reversed by thiols (DTT, β-ME, reduced glutathione, 
and cysteine) and that PTPase inactivation was reversible. However, others have shown that 
H2O2 is able to inhibit the activity of the serine/threonine phosphatases, PP1 and PP2A, and 
thiol-specific reducing agents (DTT, β-ME, and NAC) blocked this effect. Well documented 
evidence for the role of H2O2 in the signaling pathways of hormones and growth factors can be 
found in papers by Meng et al. [144, 145], who showed that different PTPases are inactivated in 
response to insulin and PDGF stimulation, and that this inactivation was dependent on ROS 
production. Moreover, in both cases, PTPase activity was associated with a decrease in the 
activation of downstream effectors of the respective pathways. Lee et al. (1998) suggested that 
inactivation of PTPases by H2O2 following EGF binding to its receptor is required for optimum 
tyrosine phosphorylation levels [18]. It is speculated that NADPH oxidase-derived ROS oxidizes 
and inactivates MAP kinase phosphatases and maintains oncogenic Ras MEK-induced activation 
of ERK [146]. 
H2O2 is produced upon growth factor stimulation of vascular SMCs and treatment with 
H2O2 causes cell growth. Since H2O2 is also involved in the regulation of PTP activity, it has 
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been proposed that H2O2 might be a necessary component of the intracellular signaling relay of 
molecules such as PDGF, EGF, angiotensin II, serotonin, and oleic acid that control ROS 

























Figure 1. Scientific model to illustrate my proposed working hypotheses relative to each specific 
aim proposed for this work. Number 1 and solid lines indicate work related to specific aim 1; 
Number 2 and dotted lines indicate work related to specific aim; Number 3 and dashed lines 
indicate work related to specific aim 3. 
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Figure 2. Localization of uterine mesenchymal cells in the developing mouse uterus. Mullerian 
duct (MD) 
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Figure 4. Leiomyoma tumors. A) Uterus with similar size to a 28-week pregnancy prior to 
myomectomy. B) Normal size uterus with 3 intramural leiomyoma tumors. Images courtesy of 
Dr Jay Goldberg, MD, MSCO, of Jefferson Medical College, Philadelphia, and Dr Peter 
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Figure 5. Leiomyoma tumors. A) Abdomen of a woman the size of a 28-week pregnancy prior to 
myomectomy. B) 16 leiomyomas removed at myomectomy in patient wishing to avoid 
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CHAPTER 3 
REACTIVE OXYGEN SPECIES MEDIATE MITOGENIC GROWTH FACTOR 
SIGNALING PATHWAYS IN HUMAN LEIOMYOMA SMOOTH MUSCLE CELLS 
 
3.1 ABSTRACT 
 Uterine leiomyomas are benign uterine tumors characterized by extracellular matrix 
remodeling, increased collagen deposition and increased smooth muscle cell (SMC) 
proliferation.  The reactive oxygen species (ROS) producing NADPH oxidase complex is 
involved in the signaling pathways of several growth factors, cytokines, and vasoactive agents 
that stimulate proliferation of a variety of cell types.  My objective was to test the hypothesis that 
ROS derived from NADPH oxidase are necessary components of the MAP kinase mitogenic 
pathway activated by platelet derived growth factor (PDGF) and epidermal growth factor (EGF) 
in leiomyoma SMCs (LSMCs). Primary cell cultures of LSMCs were used as the experimental 
model.  Results showed that stimulation of these cells with PDGF or EGF caused a marked 
increase in intracellular ROS production and that the NADPH oxidase inhibitor, DPI, blocks 
ROS production.  In addition, inhibition of ROS production by NADPH oxidase inhibitors 
blocked, in a dose-dependent manner, the EGF- and PDGF-induced increase in [3H]thymidine 
incorporation by LSMCs.  Furthermore, an exogenous source of ROS, hydrogen peroxide, was 
sufficient to stimulate [3H]thymidine incorporation in LSMCs but did not affect COL1A2 and 
COL3A1 mRNA levels.  Inhibition of the NADPH oxidase complex decreased PDGF-induced 
ERK1/2 activation whereas exogenous hydrogen peroxide induced ERK1/2 activation. This 
manuscript is the first report suggesting the presence of the NADPH oxidase system and its 
importance in mitogenic signaling pathways in LSMCs. The necessity of NADPH oxidase-
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derived ROS for EGF and PDGF signaling pathways leading to cell proliferation points to 
another potential therapeutic target for treatment and/or prevention of uterine leiomyomas. 
 
3.2 INTRODUCTION 
 Uterine leiomyomas, or fibroids, are characterized by an increase in SMC proliferation 
and excessive deposition of extracellular matrix proteins, primarily collagens type I and III [1, 2, 
33].  Recent survey studies have reported that over 600,000 hysterectomies are performed in the 
USA, and that uterine leiomyomas represent 29.4% and 41.4% of the hysterectomies in women 
ages 18-44 and 45-64, respectively [4].  Epidemiological studies have shown that seven out of 
every ten Caucasian women and eight out of every ten African-American women will eventually 
develop uterine leiomyomas [3]. 
 Ovarian steroid hormones are known to play a central role in the regulation of uterine 
leiomyoma growth because leiomyomas develop only in post pubertal and pre-menopausal 
women.  A significant reduction in tumor size is observed after the onset of menopause and in 
response to treatment with gonadotropin-releasing hormone or progesterone antagonists [59, 60].  
Steroid hormones induce mitogenic effects directly through their receptors or by regulating 
expression of growth factors such as EGF and PDGF and their respective receptors [54, 60]. 
Both EGF and PDGF receptors have previously been identified in LSMCs [70, 74].  
Furthermore, EGF and PDGF have been shown by numerous investigators to stimulate the 
proliferation of LSMCs [74, 75].  Vascular SMCs show similar mitogenic responses to these 
same growth factors [147, 148]. 
 The pathophysiology of uterine leiomyomas is similar to that of other fibrotic conditions 
such as atherosclerosis, vascular restenosis, liver, pancreatic and renal interstitial fibrosis, in 
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which an injury triggers normally quiescent cells to dedifferentiate into a myofibroblast-like, 
more proliferative phenotype [5-8].  It is likely that the development of leiomyomas may parallel 
these pathological conditions, occurring in response to some type of injury to the myometrium 
such as hypoxia.  
 Reactive oxygen species (ROS), which were once regarded as purely cytotoxic, are now 
recognized as effective second-messenger molecules regulating protein modifications, gene 
expression, cell proliferation, migration, and differentiation as well as tissue remodeling in a 
variety of cell types [10, 91, 94, 108, 112, 113, 115-117, 119].  ROS activation is biphasic [149], 
and the signaling effects can be both immediate and long-lasting.  NADPH oxidase serves as the 
primary source of intracellular ROS, specifically hydrogen peroxide, in a variety of cell types 
[150, 151]. Sundaresan and colleagues were the first to uncover the importance of increasing 
intracellular ROS levels in response to specific growth factor ligands [17]. This group showed 
that upon treatment with PDGF, ROS levels in vascular SMCs rose rapidly and returned to 
baseline within approximately thirty minutes.  Furthermore, after blocking the PDGF-stimulated 
generation of intracellular ROS, they noted a marked inhibition of MAPK activation and 
proliferation.  More recent studies have shown that growth factors (including EGF and PDGF), 
chemokines, cytokines, and vasoactive agents such as angiotensin can induce NADPH oxidase-
dependent ROS production, which in tunr activates various MAPKs that regulate downstream 
cell proliferation or matrix production [94, 112, 116].  
 The focus of my research is to gain a better understanding of the signaling pathways 
involved in regulation of uterine leiomyoma growth.  My goals in this study were to determine 1) 
whether ROS are necessary components of the signaling pathways for PDGF and EGF in 
LSMCs and 2) the potential involvement of ERK1/2 as intermediate molecules mediating the 
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effects of ROS on leiomyoma SMC proliferation.  Results show that NADPH oxidase-derived 
ROS are indeed an important component of these signaling pathways. 
 
3.3 MATERIALS AND METHODS 
3.3.1 Chemicals and Reagents 
 PDGF (120-HD) and EGF (236-EG) were purchased from R&D Systems (Minneapolis, 
MN). Diphenyleneiodonium chloride (DPI; D2926) and DMSO (D2650) were purchased from 
Sigma (St. Louis, MO). Tritiated thymidine ([3H]thymidine) (NET-027) was purchased from 
PerkinElmer. Thirty percent hydrogen peroxide (H325-100) and bovine serum albumin 
(BP1600-100) were purchased from Fisher Scientific. Restore Western Blot Stripping Buffer 
(21059), BCA protein assay kit, and SuperSignal West Pico Chemiluminescent Substrate 
(34080) were purchased from Thermo Scientific (Rockford, IL). Anti-ERK1/2 and anti-
phosphorylated ERK1/2 antibodies, and anti-mouse and anti-rabbit HRP-linked antibodies were 
purchased from Cell Signaling (Danvers, MA). Dulbecco modified Eagle medium (DMEM; 12-
614F), penicillin-streptomycin (17-602E), phenol-red-free-DMEM (PRF-DMEM, 12-917F), and 
L-glutamine (17-605E) were purchased from Biowhittaker. Dulbecco’s PBS/Modified 
(SH30264.01), fetal bovine serum (FBS; SH30071.03) and bovine calf serum (BCS; 
SH30072.03) were purchased from Hyclone. Carboxy-H2DCFDA (5-(and-6)-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate) (C400), dihydroethidium stabilized in DMSO (D23107), 
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3.3.2 Cell Culture 
 Leiomyomas were obtained from patients undergoing hysterectomy who had given 
written consent in accordance with the University of Illinois and Northwestern University IRB 
committees. Tissues were minced, digested in collagenase overnight, and then placed into flasks 
in DMEM + 5% FBS + 5%BCS which will be referred to as DMEM/10% serum.  Cells were 
characterized for expression of the smooth muscle cell specific markers α-actin and desmin, and 
for lack of expression of the fibroblast-specific marker vimentin. These primary cells were then 
cultured in DMEM/10% serum, supplemented with BCS, penicillin-streptomycin (10,000U 
pen/ml, 10,000 µg strep/ml), and L-glutamine (200 mM) in 75 cm2 cell culture flasks (Midwest 
Scientific, 90075). Cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% 
CO2. For all the experiments reported in this dissertation, cells were used between passages 3-8. 
 
3.3.3 Measurement of Intracellular ROS Production: Dihydroethidium (DHE) 
 LSMCs were cultured on 2-well collagen-coated glass slides (Becton Dickinson, 354627) 
in 2 ml per well of DMEM/10% serum at a density of 50,000 cells per well. Cells were tested 
once they attained approximately 50% confluence to prevent fluorescent dye from becoming 
trapped in the extracellular matrix. The generation of intracellular ROS was measured using 
DHE as a fluorescent probe. 
 To determine the effects of PDGF or EGF on intracellular ROS production, cells received 
the following treatments for increasing time increments of 0, 5, 10, or 15 minutes: DMEM + 
0.1% BSA, 10 ng/ml PDGF (maximal dose), or 100 ng/ml EGF (maximal dose). All treatments 
were applied using phenol-red-free-DMEM (PRF-DMEM) containing 0.1% BSA, pen-strep, and 
L-glutamine. Cells were washed once using phenol red free-DMEM/0.1% BSA. Cells were then 
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loaded with the fluorescent DHE dye (10 µM) in phenol red free-DMEM/0.1% BSA for 20 
minutes. This dye can passively enter cells and produces a red fluorescent signal upon its 
oxidation by intracellular ROS. The oxidized ethidium bromide then becomes intercalated within 
the cell’s DNA, producing a long-lasting fluorescence.  After removal of the dye, cells were 
washed twice with phenol red free-DMEM.  The medium was then removed and cells were 
visualized using a Zeiss Axiovert 25 fluorescence microscope. Pictures were taken using a Zeiss 
Axiocam camera to record fluorescent images.  An increase in intracellular fluorescence 
indicated an increase in intracellular ROS production. 
 
3.3.4 Measurement of Intracellular ROS Production: Carboxy-H2DCFDA 
 LSMCs were cultured in 35mm µ-dishes (80136) from Ibidi (Munchen, Germany) in 800 
µl of DMEM/10% serum at a density of 2,000 cells per dish. Once cells attained 50% confluence 
the experiment was performed. Cells were washed  three times in warm DPBS and carboxy-
H2DCFDA dye was added to the cells in 800 µl of DPBS at a 10 µM concentration. After 15 
minutes of incubation, dye was removed and cells were washed two times and treatment was 
added. Cells were exposed to either DPBS alone (negative control), H2O2 (10 µM) (positive 
control), EGF (50 ng/ml) or PDGF (10 ng/ml) in DPBS for 15 minutes. Growth factors were 
added in absence or presence of 25 µM DPI. After treatment, cells were washed two times and 
images were immediately captured using a fluorescence microscope (Zeiss Axiovert 200M). 
 
3.3.5 Densitometric Quantification of Fluorescence Images 
 Individual cells were randomly selected from several different microscopic fields, and 
fluorescence as well as DIC-Nomarski images were captured and saved as TIFF files. Images 
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were loaded and analyzed on Axiovision software (Zeiss). The intracellular compartment of cells 
was determined by using DIC images. To be consistent with regards to the areas of fluorescence 
measurements circles were drawn around the nucleus of every cell. The average of the 
fluorescence measurements from each cell was taken and used for statistical analysis. 
 
3.3.6 [3H]Thymidine Incorporation Assays: Effect of Exogenous ROS 
 LSMCs were cultured in 96-well plates in 200 µL of DMEM/10% serum at a density of 
4,000 cells per well. Once cells attained 80% confluence, they were growth-arrested in 
DMEM/0.5% FBS for 48 hours to synchronize the cells.  
 To examine stimulation of cell proliferation by exogenous ROS, cells were placed in 
fresh DMEM/0.5% FBS and were pulse-treated once each hour for five hours with hydrogen 
peroxide (10, 50, 100 or 200 µM). [3H]thymidine (0.4 µCi) was added to the cells at the 
beginning of the five-hour treatment. Cells were then harvested and counted in a beta-
scintillation counter to quantitate [3H]thymidine incorporation. DNA synthesis was recorded as 
counts per minute (cpm). 
 
3.3.7 [3H]Thymidine Incorporation assays: Effect of ROS Inhibitor 
 LSMCs were cultured as described in the previous section. To determine whether 
proliferation observed in response to EGF or PDGF could be inhibited by treatment with a ROS 
inhibitor, cells were maintained in DMEM/0.5% FBS and pretreated with 200 µl of 
diphenyleneiodonium chloride (DPI) at increasing concentrations of 0, 5, 25 or 50 µM for 60 
minutes.  DPI was then removed and cells were washed twice with DMEM/0.5% FBS and then 
treated with either 50 ng/ml EGF or 10 ng/ml PDGF for 24 hours. Control cells that were not 
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pretreated with the inhibitor were either treated with EGF (50 ng/ml), PDGF (10 ng/ml), or no 
growth factor.  Cells were labeled during the final 6 hours of treatment with [3H]thymidine (0.4 
µCi). Cells were then harvested and counted using a beta-scintillation counter to measure the rate 
of [3H]thymidine incorporation. DNA synthesis was recorded as counts per minute (cpm). 
 
3.3.8 Assessment of Proliferation Using Cell Counts 
 LSMCs were plated in 6-well plates in 2 ml of DMEM/10% serum at a density of 50,000 
cells per well. Upon attaining 80% confluence cells were growth arrested in DMEM/0.5% FBS 
for 24 hours and experiments were performed. To determine the effects of H2O2 on cell numbers, 
cells were given new medium every hour for 8 hours per day, over a 2 day period. Treatments 
consisted of DMEM/0.5% FBS or H2O2 (20 µM and 100 µM). To determine the effects of DPI 
on cell numbers of EGF- and PDGF-stimulated cells, cells were exposed to either DMEM/0.5% 
FBS, EGF (50 ng/ml), or PDGF (10 ng/ml) for 48 hours. Growth factors were added in the 
absence or presence of DPI (25 µM). At the end of the treatment period cells were detached with 
1 ml of trypsin for 8 minutes, mixed with 1 ml of DMEM/10% serum and counted using a 
hemocytometer.  
 
3.3.9 COL1A2 and COL3A1 Gene Expression 
 LSMCs were grown in 60 mm culture dishes and allowed to attain 80% confluence. Cells 
were then washed and switched to DMEM/0.5% FBS.  Cells then were given hourly pulses of 
hydrogen peroxide (20 µM) for 5 hours or were treated with one-200 µM hydrogen peroxide 
pulse for 24 hrs.  Total RNA was isolated from cells using Trizol Reagent. Complementary DNA 
synthesis was performed and followed by qRT-PCR to determine relative fold differences in 
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collagen type 1 alpha 2 (COL1A2) and collagen type 3 alpha 1 (COL3A1) mRNA expression in 
response to ROS. Applied Biosystems TaqMan Gene Expression Assay for COL3A1: 




 LSMCs were serum-starved for1 hour in 60 mm dishes. Two hundred microliters of 
concentrated hydrogen peroxide (10 µM final concentration), EGF (50 ng/ml final 
concentration), or PDGF (10 ng/ml final concentration) were added directly to the cells and 
treatments continued for the specified time periods. When pretreatment with NADPH oxidase 
inhibitor was necessary, cells were exposed to DPI for 60 minutes and concentrated growth 
factors were then added to the cells in the presence of the inhibitor. Cell lysates were harvested 
by removing medium and adding warm (95ºC) 1X-Laemmli sample buffer (LSB) (2% SDS, 10% 
glycerol, 62.5 mM Tris, pH 6.8). Cells were scraped off the dishes, added to a 1.5 ml tube, 
sonicated (10 pulses) and stored at -20ºC. BCA assays were performed on the cell lysates to 
determine protein concentrations. Either 5 µg (ERK1/2 blots) or 45 µg (EGF-R or PDGF-R 
blots) of total protein were loaded on SDS-PAGE gels (12%) and run initially at 80 V for 30 
minutes, then at 150 V for 90 minutes.  Protein transfer was carried out at 60 mA for 16 hours at 
room temperature. Primary antibody (anti-phosphorylated ERK1/2 1:2000 in 5% milk; anti-
ERK1/2 1:1000 in 3% BSA; anti-phoshporylated EGF-R and anti-PDGF-R 1:500 in 5% milk; 
anti-EGF-R and anti-PDGF-R 1:500 in 3% BSA) incubation was performed for 90 minutes at 
room temperature. HRP-conjugated secondary antibody was incubated with membranes in 5% 
milk for 60 minutes at room temperature (1:10,000).  The SuperSignal West Pico 
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Chemiluminescent Substrate kit was used as substrate for HRP. Membranes were first probed 
with anti-phosphorylated ERK1/2 antibody, and then reprobed with anti-total ERK1/2 as a 
loading control. Membranes were stripped with Restore Western Blot Stripping buffer from 
Thermo Scientific (Rockford, IL) before being reprobed. 
 
3.3.11 Densitometric Analysis of Western Blots 
 Films developed after exposure to chemiluminescence on the membranes were scanned 
and images saved at high resolution in a TIFF format. Images were analyzed using the ImageJ 
software from NIH (available at http://rsbweb.nih.gov/ij/download.html). Software was calibrated 
for optical density measurements using a Kodak no. 3 calibrated step tablet available at 
http://rsb.info.nih.gov/ij/docs/examples/calibration/. Bands of interest were measured by drawing 
the smallest rectangle capable of measuring the optical density of all the bands. The same 
rectangle was used to measure all the bands in one film. Measurements of bands referring to the 
activated form of the proteins (phosphorylated form) were normalized for loading differences 
using measurements obtained from the bands obtained using antibodies that recognized all forms 
of the specific proteins (loading control). Graphs represent LSmeans and SEM. 
 
3.3.12 Statistical Analysis 
 Quantitative RT-PCR experiments were performed using the relative standard curve 
method. To show changes in gene expression relative to control level (control set as 1), each 
biological replicate was normalized to the average of the control group within each experiment. 
Relative fold difference values from qRT-PCR experiments and cpm values from [3H]thymidine 
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incorporation experiments in each experiment were checked for normality and common variances, 
respecting the assumptions for performing analysis of variance. All distributions were normal. 
Statistical analysis for all experiments followed the same approach. A completely randomized 
design corresponding to the following linear model was used: Xik = µ + τi + εik, where Xik: an 
observation, µ: population mean, τi: effect of ith treatment, εik: error term. The Linear model for 
densitometry analysis of the western blots used values for total ERK1/2, EGF-R or PDGF-R as 
a covariate. A priori comparisons determined by contrasts were used to minimize testing the null 
hypothesis multiple times (α=0.05). The contrasts were only performed when ANOVA 
indicated significant effect due to treatment. The data analyses for this paper were generated 
using SAS software (SAS Institute Inc.). 
 
3.4 RESULTS 
3.4.1 EGF and PDGF Stimulate Intracellular ROS Generation 
 To test the hypothesis that ROS are necessary mediators of EGF and PDGF signaling 
pathways, I first examined whether EGF or PDGF would induce an increase in intracellular ROS 
production in LSMCs. Figure 10A indicates an increase in fluorescence after 15 minutes of 
stimulation with PDGF and the bright field image shows that fluorescence was specifically 
observed intracellularly. Cells were loaded with DHE fluorescent dye following growth factor 
treatment and the presence of fluorescence indicated oxidation of DHE and, therefore, the 
presence of ROS. Intracellular fluorescence was observed in cells following treatment with either 
10 ng/ml PDGF or 100 ng/ml EGF, and fluorescence increased over time, with maximum 
fluorescence occurring after 15 minutes of treatment (Figure 10B). However, the effects of EGF 
or PDGF treatment on ROS production were evident as early as 5 minutes. 
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3.4.2 NADPH Oxidase Inhibitor Blocks EGF- and PDGF-Stimulated ROS Production 
 To capture higher power images and get better intracellular resolution with the 
intracellular ROS detection experiments I used another oxidation sensitive dye, carboxy-
H2DCFDA. I first tested whether this dye was sensitive to oxidation by H2O2. Indeed, upon 
addition of H2O2 (10 µM) to the culture medium, the compound entered the cells readily and 
induced a significant increase in intracellular fluorescence (Figure 11A). In the same experiment 
I also confirmed the increase in ROS production after LSMC treatment with EGF and PDGF. 
Similar results were obtained when using DHE dye (Figures 11A and 10A, respectively). After 
validating the carboxy-H2DCFDA dye, my next goal was to validate the compound 
diphenyleneiodonium (DPI) as an inhibitor of the enzymatic complex which Ihypothesize is 
responsible for ROS production (NADPH oxidase). When cells were treated with EGF or PDGF 
in the presence of DPI (25 µM) for 15 minutes there was a significant drop in the amount of 
fluorescence observed intracellularly. DIC-Nomarski images indicate the localization of the 
cells, and when merged with the fluorescence channel, support the intracellular ROS 
localization. These results show that carboxy-H2DCFDA is a highly sensitive probe that can 
detect changes in intracellular ROS concentrations; DPI can block growth factor-induced ROS 
production by LSMCs; and that the NADPH oxidase complex is active and potentially involved 
with EGF and PDGF signaling pathways. Figure 11B shows the densitometric analysis of the 
fluorescence images as a means of quantitatively comparing the different treatments. 
 
3.4.3 NADPH Oxidase Inhibitor Blocks EGF- and PDGF-Stimulated Proliferation of LSMCs 
 Based upon the results showing that ROS are produced in response to EGF and PDGF, 
the next logical step was to test the hypothesis that ROS are a necessary component of the EGF 
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and PDGF mitogenic pathways and that NADPH oxidase is the enzymatic complex involved in 
this receptor-mediated ROS production. After validating DPI, Iused this NADPH oxidase 
inhibitor to block ROS generation in the presence of either EGF or PDGF.  Ithen assessed the 
effect of DPI on EGF- and PDGF-induced LSMC proliferation by measuring changes in DNA 
synthesis using [3H]thymidine incorporation assays.  Pretreatment of cells with increasing 
concentrations of DPI before adding EGF resulted in significant inhibition of proliferation when 
compared to those cells treated with EGF alone (Figure 12A).  In fact, the levels of DNA 
synthesis at the two higher concentrations were reduced to levels below those observed in the 
controls (0.5% FBS only).   Similarly, when cells were exposed to DPI prior to treatment with 
PDGF, a reduction in growth factor-stimulated proliferation was again observed (Figure 12B). 
 The effects of DPI on EGF- or PDGF-stimulated cell proliferation were significant. This 
inhibitory effect was dose-dependent, as the highest concentration of DPI blocked DNA 
synthesis almost completely.  
 To confirm whether the results obtained with the [3H]thymidine incorporation assays 
were paralleled by similar changes in cell number Iperformed cell count experiments using a 
hemocytometer. Cells exposed to either EGF or PDGF in the presence of DPI had a dramatic 
decrease in cell number in comparison to growth factors alone (Figure 12C). Similar results were 
observed with myometrial SMCs (APPENDIX B). 
 
3.4.4 Exogenous H2O2 Stimulates LSMC Proliferation 
 After demonstrating that inhibition of the ROS-producing NADPH oxidase complex 
inhibited growth factor-induced cell proliferation, Itested whether an exogenous source of ROS 
was sufficient to induce LSMC proliferation. ROS are extremely labile and, therefore, difficult to 
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use as a treatment for cells in vitro.  In light of this characteristic of hydrogen peroxide, Iused 
increasing concentrations of exogenous hydrogen peroxide (10 to 200 µM) as pulse treatments 
once per hour for five hours and then assessed change in DNA synthesis. Interestingly, hydrogen 
peroxide at 10 µM increased DNA synthesis, whereas higher concentrations of the compound 
(50 µM and 100 µM) had no effect compared to control, and 200 µM was inhibitory (Figure 
13A).  These data indicate that within the range of concentrations used it was possible to separate 
the specific mitogenic effects of hydrogen peroxide from its inhibitory effects, which may be 
related to oxidative stress. Cell count experiments confirmed that at relatively low concentrations 
(20 µM) H2O2 causes in increase in cell number compared to untreated control, whereas at 
higher concentrations (100 µM), it inhibited cell proliferation (Figure 13B). Similar experiments 
did not detect an effect of either hydrogen peroxide concentration tested in myometrial SMCs 
(APPENDIX B). 
 
3.4.5 NADPH Oxidase Inhibitor Blocks PDGF-Stimulated ERK1/2 Activation 
 To elucidate the inhibitory pathway further Iinvestigated the involvement of the well-
known mitogen-activated protein kinase pathway on ROS-dependent proliferative responses of 
LSMCs, specifically ERK1/2. Both EGF and PDGF induced phosphorylation of ERK1/2 within 
five minutes of treatment with maximum phosphorylation occurring between 10 and 15 minutes 
(Figure 14). Similar results were observed with myometrial SMCs (APPENDIX C). I 
hypothesized that activation of ERK1/2 occurs downstream of the increase in ROS production 
and that inhibition of ROS production would reduce the level of ERK1/2 phosphorylation in 
response to EGF or PDGF treatment. No effects of DPI treatment on EGF-induced ERK1/2 
activation were observed (Figures 15A and 15B). However, pre-treatment of LSMCs with DPI 
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reduced PDGF-induced ERK1/2 activation.  This result is indicated by the decrease in intensity 
of the phosphorylated ERK1/2 band from the cells treated with 50 µM of DPI in comparison to 
that observed for growth factor treatment alone (Figure 15C and 15D). Results showing 
inhibition of PDGF-induced ERK1/2 activation by DPI and lack of inhibition of EGF-induced 
ERK1/2 activation suggest a specific regulation of PDGF signaling pathway by ROS. Similar 
results were observed with myometrial SMCs (APPENDIX D). 
 To test whether DPI was potentially having toxic effects I decided to focus on the 
activation of molecules that are not regulated by ROS and would not be affected by DPI unless 
the inhibitor is having non-specific effects. I measured the ability of EGF-R or PDGF-R to 
undergo autophosphorylation upon exposure to EGF or PDGF in the presence of DPI in LSMCs. 
Although there was a trend towards a decrease in PDGF-R autophosphorylation in the presence 
of increasing concentrations of DPI, there was no statistical significance. Figure 16 provides 
evidence that LSMCs were able to respond to both growth factors even in the presence of the 
highest DPI concentration. This result is supported by the lack of a statiscally significant 
reduction of EGF-R and PDGF-R autophosphorylation (Figures 16B and 16D). Similar results 
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3.4.6 Exogenous H2O2 Stimulates ERK1/2 in LSMCs 
 I next tested whether treatment with exogenous hydrogen peroxide was sufficient to 
induce ERK1/2 phosphorylation. Similarly to the response observed in [3H]thymidine 
incorporation experiments, exogenous hydrogen peroxide alone induced activation of the 
ERK1/2 pathway (Figure 17). ERK1/2 reached maximum activation within 10 and 15 minutes 
after hydrogen peroxide treatment returning to basal levels after 30 minutes. Similar results were 
observed with myometrial SMCs (APPENDIX F). 
 
3.4.7 Effects of Exogenous H2O2 on COL1A2 and COL3A1 Gene Expression in LSMCs 
 Based on results showing that H2O2 had a positive effect on LSMC proliferation and 
ERK1/2 activation, I tested whether H2O2 might also be involved in regulating collagen 
expression.  Cells were either untreated, given five hourly pulses of 10 µM H2O2, or a higher 
concentration of H2O2 (100 µM) for 24 hrs.  Total RNA was harvested and analyzed for changes 
in mRNA levels of COL1A2 and COL3A1 using qRT-PCR.  Exogenous H2O2 did not alter 
COL1A2 and COL3A1 mRNA expression in LSMCs (data not shown).  Treatment with either 
EGF or PDGF also did not affect levels of collagen mRNAs (data not shown).   
 
3.5 DISCUSSION 
 The goal of this study was to determine whether ROS are necessary components of the 
PDGF and EGF signaling pathways for LSMC proliferation.  These results are the first to 
demonstrate that ROS generated by the NADPH oxidase system in LSMCs are involved as 
intermediates in the signaling pathway of these growth factors. The main findings of this study 
are that 1) LSMCs produce ROS in response to EGF and PDGF; 2) ROS are necessary and 
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sufficient to induce LSMC proliferation; and 3) ROS are necessary and sufficient to induce a 
fraction of ERK1/2 activation in LSMCs. 
 To determine the role of reactive oxygen species in the mitogenic signaling pathways of 
EGF and PDGF in LSMCs, I first needed to show that these growth factors induced ROS 
generation in such cells.  EGF and PDGF have been shown previously to stimulate intracellular 
ROS production in other cells types [17, 112, 115, 152].  This study is the first to show that both 
PDGF and EGF induce intracellular ROS generation in LSMCs.  This receptor-mediated ROS 
production was initially discovered in cells of the immune system and shown to be derived from 
the plasma membrane flavohemoprotein complex NADPH oxidase [127].  One of the first 
reports of Matsubara and Ziff [153] focusing on non-immune cells from showed that endothelial 
cells released superoxide in response to specific cytokines. Since this first evidence linking ROS 
generation to regulation of inflammatory responses, many other groups have become interested 
in the role of the NADPH oxidase complex in hyperproliferative disorders [11].  More recently, 
NADPH oxidase-derived ROS have been implicated as a necessary component of numerous 
signaling pathways and associated with specialized cell functions [11, 121, 152-154].   
 If ROS are a necessary component of the PDGF and EGF signaling pathways then the 
addition of exogenous ROS should mimic the effects of these growth factors. In fact, when 
treated with exogenous hydrogen peroxide, LSMCs exhibited a notable increase in DNA 
synthesis and cell number. The pathway by which exogenous ROS produced this effect in 
LSMCs is still unknown and may not be the same as that of EGF or PDGF. One of the first 
evidences of the participation of ROS, specifically hydrogen peroxide, in signaling pathways was 
provided by experiments showing hydrogen peroxide-dependent glucose oxidation in response to 
insulin [155]. ROS were later shown to be required for cell growth and transformation [10, 11, 
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121].  Hydrogen peroxide has been recognized as a signaling molecule since investigators 
determined that its concentration can rapidly and transiently increase in response to receptor-
mediated signaling events.  Furthermore, hydrogen peroxide undergoes quick enzymatic 
degradation, is diffusible, and can act in a specific and reversible fashion [14, 15].  Rao and Berk 
[156] demonstrated that hydrogen peroxide caused an increase in [3H]thymidine incorporation in 
vascular smooth muscle cells, in agreement with what my results have shown.  In addition, other 
studies have demonstrated that a shift in intracellular ROS levels towards a more oxidizing 
environment stimulates the G1 to S phase transition in the cell cycle [12, 13].   
 Experiments focusing on the role of ROS in normal cell function are complicated by the 
fact that ROS are extremely short-lived molecules.  In the present study a low hydrogen peroxide 
concentration of 10 µM was added as a pulse, every hour for 5 hours, in contrast to 200 µM 
every 3 hours for 24 hours by Rao and Berk [156]. The replenishment system allowed me to 
overcome the problem with hydrogen peroxide being labile and degrading rapidly over time, as 
well as to the use of concentrations which may more closely resemble physiological levels. 
Although it is difficult to determine what the physiological levels are and how specific hydrogen 
peroxide action is, I used concentrations that are 20 times lower than several other studies. 
Furthermore, COL1A2 and COL3A1gene expression was not affected by the same hydrogen 
peroxide administration regimen suggesting that the higher proliferation rate was not due to 
increased collagen deposition, or to a general non-specific effect of hydrogen peroxide. I also 
observed that the use of concentrations above 50 µM abolished even basal levels of proliferation 
confirming the negative effect of high levels of ROS on cells. 
 Pretreatment with the NADPH oxidase inhibitor DPI significantly inhibited EGF- and 
PDGF-induced proliferation of LSMCs. These data support my hypothesis that ROS are critical 
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intermediates in the mitogenic signaling pathways of EGF and PDGF and also suggests for the 
first time the presence of the NADPH oxidase complex in the uterus. DPI has been used 
successfully by numerous other laboratories to prevent hormone/growth factor-induced, ROS-
dependent, cell proliferation in vascular smooth muscle cells [157-159]. DPI pretreatment did not 
appear to have caused cytotoxic effects at the concentrations used, as cells were able to respond 
to growth factor treatment with receptor autophosphorylation. This finding suggests a tight 
regulation of ROS production in the cell. When ROS levels are too high, it is believed that ROS 
function as potent oxidizing agents, potentially causing oxidative damage and cytotoxic effects. 
However, if intracellular ROS concentrations fall below a critical level crucial cellular signaling 
events might be disrupted. 
 Inhibition of PDGF-induced ERK1/2 activation by DPI and induction of ERK1/2 
activation by exogenous hydrogen peroxide suggest ROS are necessary and sufficient to trigger 
the ERK1/2 signaling pathway associated with PDGF. The fact that the responsiveness of 
LSMCs to EGF with regards to ERK1/2 activation seemed unaffected by the presence of DPI 
may suggest another level of specificity to the role of ROS in regulating PDGF signaling 
pathway. Although the present study provides new information regarding the role of ROS in 
leiomyoma SMCs, ERK1/2 activation in response to hydrogen peroxide has been observed 
previously in vascular smooth muscle cells, in agreement with my results [99]. Several studies 
have reported activation of a variety of specific downstream targets including ROS-dependent 
p38MAPK activation, but not ERK1/2 [94], activation of both ERK1/2 and MAPK14 [114], as 
well as activation of only MAPK8 [116]. Some of the studies utilized NADPH oxidase inhibitors 
or ROS scavengers to confirm participation of ROS in these signaling pathways, whereas others 
tested the effects of exogenous hydrogen peroxide at concentrations ranging from 5 to 100 fold 
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higher than those used in the current study. The use of different hydrogen peroxide 
concentrations may explain the discrepancies between results I obtained and those of others.  
ROS are involved in the activation of several signaling events including regulation of EGF and 
PDGF receptor activation or transactivation through induction of CSK activity [113, 160], 
VEGF-dependent HIF1 activation [161], IL1-dependent regulation of MP3K14 [162], TGFB1-
dependent activation of EGR1 gene expression [163], and ultimately, the regulation of protein 
tyrosine phosphatase activity.  Hydrogen peroxide cannot directly phosphorylate proteins, but it 
can specifically oxidize certain cysteine residues within protein tyrosine phosphatases, which 
become then unavailable to interact with phosphate substrates rendering the enzyme inactive [14, 
15].  Redox regulation of protein tyrosine phosphatases such as PTEN, PTPN1, ACP1, and 
CDC25C has been reported [16, 18-20]. Furthermore, the importance of PTPs in regulating the 
level of activation of growth factor receptors and the role of reductases in counteracting the 
effects of oxidants on PTPs during cell signaling have also been confirmed [21, 22, 164]. 
Whether NADPH oxidase-derived ROS affect proliferation and activation of ERK1/2 pathways 
in LSMCs by regulating protein tyrosine phosphatase activity remains to be tested. 
 The involvement of ROS generated through the NADPH oxidase complex in the 
development of chronic diseases including fibrotic conditions such as pulmonary, hepatic and 
pancreatic fibrosis has been proposed recently by other investigators [9].  Many of these 
disorders are associated with overproduction of ROS and are linked to higher expression of the 
NADPH oxidase subunits [9].  The increased production of ROS may occur as part of an 
inflammatory response and may contribute to the abnormal cell proliferation that is observed in 
conditions such as atherosclerosis or diabetic vascular disease.  Drugs that can target the 
NADPH oxidase complex such as specific inhibitors of the NOX/DUOX family members 
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represent potential therapeutic approaches for treatment of these chronic diseases [126].  Uterine 
leiomyomas are also an example of a chronic fibrotic disease and thus, the characterization and 
understanding of the NADPH oxidase complex in LSMCs may be important for future directions 
in treatment of these tumors. 
 In summary, the findings of my research suggest that reactive oxygen species are an 
important component of the EGF and PDGF signaling pathways involved in LSMC proliferation. 
Specifically regarding the PDGF signaling pathway, these data suggest that the activation of 
ERK1/2 is an important step following PDGF-induced ROS production, which may be necessary 
for ROS-induced LSMC proliferation. This mechanism is likely occurring through the 
stimulation of NADPH oxidase and the subsequent generation of intracellular ROS. My findings 
provide the first evidence of (1) ROS as a second messenger in LSMCs proliferation, and (2) of a 
non-phagocytic NADPH oxidase complex in leiomyoma smooth muscle cells. This research 
presents a novel target for the development of preventive strategies or therapeutic approaches to 
treat uterine leiomyomas through the targeting of intracellular ROS and, specifically, NADPH 
oxidase. Although no differences were observed between normal myometrial cells and 
leiomyoma cells in regards to the influence of NADPH oxidase-derived ROS on the signaling 
pathways examined, the presence of the complex in myometrial and leiomyoma cells provides 
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3.6 FIGURES 
 
Figure 10. Intracellular ROS production by LSMCs increases in response to treatment with EGF 
or PDGF. (A) Left panel: Intracellular ROS production is indicated by the presence of red 
fluorescence in LSMCs in response to PDGF (10 ng/ml) treatment for 15 minutes; Right panel: 
Bright field image indicating that the fluorescence is located specifically within the LSMCs; (B) 
LSMCs were exposed to DMEM/0.1% BSA (negative control), EGF (100 ng/ml), or PDGF (10 
ng/ml) for increasing time periods up to 15 minutes. An increase in fluorescence indicated an 
increase in intracellular ROS production. (n=3. Representative image of LSMC response). 
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Figure 11. The NADPH oxidase inhibitor DPI blocks PDGF- and EGF-stimulated intracellular 
ROS production. An increase in fluorescent signal indicates ROS production. (A) Rows indicate 
different combinations of treatments; the left column shows bright field DIC-Nomarski, the 
middle column shows the fluorescent signal (Carboxy-H2DCFDA), and the right column is the 
merged image indicating intracellular ROS production; (B) Graphic representation of the 
LSmeans ± SEM of fluorescent signal from cells exposed to different treatments. Different 
capital letters indicate statistical difference (p<0.05). [n=3. Representative images of LSMCs 
response were used for (A)]. 
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Figure 12. The NADPH oxidase inhibitor DPI blocks PDGF- and EGF-stimulated proliferation 
of LSMCs. (A) Effects of DPI on LSMC DNA synthesis in the presence of 50 ng/ml EGF; (B) 
Effects of DPI on LSMC DNA synthesis in the presence of 10 ng/ml PDGF. (C) Effects of DPI 
on LSMC numbers in response to EGF and PDGF. Cell numbers were determined by manual 
counting on a hemocytometer. (n=3. Bars represent LSmeans ± SEM. Different capital letters 
indicate statistical difference p<0.05).   
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Figure 13.  Exogenous H2O2 affects LSMC proliferation. (A) Effects of H2O2 pulses (10, 50, 100 
and 200 µM) on DNA synthesis in LSMCs. (B) Effects of H2O2 pulses (20 and 100 µM) in 
LSMC number. Cell numbers were determined by manual counting using a hemocytometer. 
(n=3. Bars represent LSmeans ± SEM. Different capital letters indicate statistical difference 
p<0.05).  
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Figure 14.  EGF and PDGF induce phosphorylation of ERK1/2 in LSMCs.  (A) Immunoblot for 
time-course of ERK1/2 activation in response to EGF; (B) time-course of ERK1/2 activation in 
response to EGF; (C) Immunoblot for time-course of ERK1/2 activation in response to PDGF; 
anti-total ERK1/2 (tERK1/2) were used as loading control. Graphs represent the densitometric 
analysis of the immunoblots; (D) time-course of ERK1/2 activation in response to PDGF; (n=3. 
Bars represent LSmeans ± SEM. Line above 2 bars indicate both time-points were merged and 
compared to the other time-points. Asterisk above line indicates statistical difference in 
comparison to other time-points p<0.05).  
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Figure 15. The NADPH oxidase inhibitor DPI blocks PDGF-stimulated ERK1/2phosphorylation 
in LSMCs.  (A) Immunoblot for ERK1/2 activation in response to EGF in the presence or 
absence of DPI; (B) Effects of DPI on EGF-induced ERK1/2 activation; (C) Immunoblot for 
ERK1/2 activation in response to PDGF in the presence or absence of DPI; anti-total ERK1/2 
(tERK1/2) were used as loading control. Graphs represent the densitometric analysis of the blots; 
(D) Effects of DPI on PDGF-induced ERK1/2 activation; (n=3. Bars represent LSmeans ± SEM. 
Asterisk above line connecting 2 treatment groups indicates statistical difference between the 
connected groups p<0.05).   
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Figure 16. The NADPH oxidase inhibitor DPI does not affect EGF or PDGF receptor activation. 
(A) Immunoblot for EGF-R activation in response to EGF in the presence or absence of DPI; (B) 
Effects of DPI on EGF-R activation; (C) Immunoblot for PDGF-R activation in response to 
PDGF in the presence or absence of DPI; anti-total EGF-R (tEGF-R) and anti-total PDGF-R 
(tPDGF-R) were used as loading control. Graphs represent the densitometric analysis of the 
blots; (D) Effects of DPI on PDGF-R activation; (n=3. Bars represent LSmeans ± SEM. Asterisk 
above line connecting 2 treatment groups indicates statistical difference between the connected 
groups p<0.05). 
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Figure 17. Exogenous H2O2 stimulates Erk1/2 phosphorylation in LSMCs.  (A) Immunoblot for 
time-course of ERK1/2 activation in response to H2O2; anti-total ERK1/2 (tERK1/2) were used 
as loading control. Graphs represent the densitometric analysis of the blots showing the time-
course of ERK1/2 activation in response to exogenous H2O2; (n=3. Bars represent LSmeans ± 
SEM. Line above 2 bars indicate both time-points were merged and compared to the other time-
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CHAPTER 4 
CHARACTERIZATION OF THE NADPH OXIDASE COMPLEX IN NORMAL 
MYOMETRIAL AND LEIOMYOMA SMOOTH MUSCLE CELLS 
 
4.1 ABSTRACT 
Uterine leiomyomas or fibroids are benign tumors that affect over 70% of women and are 
characterized by increased proliferation of smooth muscle cells (SMCs) as well as increased 
deposition of collagens type I and III. Reactive oxygen species (ROS) have been implicated as 
important players in the development of other fibrotic disorders with similar pathogenesis such 
as liver fibrosis and atherosclerosis. My goal was to determine the expression pattern of the 
components of the ROS-generating enzymatic complex, NADPH oxidase, in leiomyoma and 
myometrial SMCs as well as to study the mechanism of activation of the complex in these cell 
types. I used qRT-PCR to assess mRNA levels and immunohistochemistry to assess protein 
localization. The mechanism of activation was studied by focusing on the expression and 
phosphorylation of the cytosolic NADPH oxidase subunit, p47phox, by immunofluorescence 
staining and immunoblotting after treatment with PDGF. Manipulations of PKC activity by the 
PKC inducer PMA and PKC inhibitors Bis and Go-6983 were used to determine the involvement 
of PKC in PDGF-induced ROS production and Erk activation. Results indicate that several genes 
encoding NADPH oxidase complex components are expressed in leiomyoma and myometrial 
tissues, and that p47phox protein is also found in both tissues. Messenger RNA data showed the 
existence of a subset of tumors with upregulation of the NADPH oxidase complex in comparison 
to their autologus normal myometrium. I also showed that PDGF and EGF treatment induced 
p47phox enrichment within lipid rafts. Moreover, stimulation of the PKC pathway with PMA led 
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to Erk phosphorylation and ROS production, whereas inhibition of PKC reduced PDGF-induced 
Erk phosphorylation and ROS production. The present study is the first to show the presence of 
the NADPH oxidase enzymatic complex in leiomyoma amd myometrial tissues. The 
upregulation of NADPH oxidase components commonly associated with increased ROS 
production may be involved in the development of a subset of leiomyoma tumors. Furthermore, 




Uterine leiomyomas are non-cancerous tumors characterized by increased proliferation of 
uterine SMCs and extensive deposition of ECM, primarily collagens type I and III [2, 32]. It has 
been estimated that over 70% of women have leiomyoma tumors, although only approximately 
25% of them are symptomatic [3]. This disorder has a significant economic impact due to the 
fact that it is the leading indication for hysterectomies with an estimated 240,000 leiomyoma-
related hysterectomies carried out every year in the US [4]. Leiomyoma tumors are responsive to 
ovarian steroids and a large range of growth factors. In addition leiomyoma SMCs can produce 
their own supply of growth factors including PDGF. Leiomyoma SMCs produce and secrete 
PDGF and its expression is induced by estrogen but suppressed by GnRH agonists [60, 66]. 
PDGF stimulates proliferation of myometrial and leiomyoma SMCs. More recently 
PDGF has been shown to alter chromatin structure of around the promoter regions of SMC-
specific genes in vascular SMCs and downregulate their expression in favor of growth-
responsive genes implying a potential role for PDGF in the regulation of the phenotypic switch 
observed in VSMCs undergoing local injury [30, 75, 165]. PDGF can also trigger a receptor-
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mediated activation of ROS production, which is known to be an important component of the 
PDGF signaling pathway in different cell types including leiomyoma cells [11, 17, 165]. 
Excessive production of ROS has been implicated with the development of numerous 
disorders such as liver and lung fibrosis [9, 126]. Higher expression of NADPH oxidase 
components has also been associated with excessive ROS production, however excessive 
stimulation of the complex could also be a reason for higher ROS levels. Activation of NADPH 
oxidase in phagocytes requires phosphorylation of cytosolic p47phox protein because this event 
leads to conformational changes that expose specific amino acids allowing for interaction with 
the membrane-bound components of the complex, specifically p22phox [129]. The mechanisms 
regulating the activation of NADPH oxidase in myometrial and leiomyoma SMCs are currently 
not known. However, in fibroblasts, Catarzi et al. (2005) determined that PKC and PI3K are 
involved in PDGF-induced ROS production [113]. 
ROS are short-lived molecules and once produced can be readily degraded by antioxidant 
enzymes, unless the levels of ROS production overcomes the rate of degradation leading to 
accumulation and intracellular damage. Efficient utilization of a controlled and transient increase 
in ROS production in a signaling pathway context can be reached by reorganization and 
relocation of molecules involving approximation of the ROS-producing NADPH oxidase 
complex and oxidation-sensitive targets. An interesting mechanism used by cells to bring 
signaling molecules in close proximity by creating a micro-intracellular environment involves 
cell membrane structures called lipid rafts. Lipid rafts are cholesterol and sphingolipid rich 
plasma membrane microdomains that serve as an intracellular compartment for signaling [166]. 
NADPH oxidase has been detected in lipid rafts and its compartmentalization and control of 
spatial distribution appears to be related to localization in lipid rafts [167]. The goal of my 
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studies was to determine the expression pattern of the components of the ROS-generating 
enzymatic complex, NADPH oxidase, in leiomyoma and myometrial SMCs as well as to study 
the mechanism of activation of the complex in these cell types. 
 
4.3 MATERIAL AND METHODS 
4.3.1 NADPH oxidase components mRNA expression 
Total RNA was isolated from 10-paired (collected from the same patient) myometrial and 
leiomyoma tissue specimens. NanoDrop spectrophotometer from Thermo Scientific 
(Wilmington, DE) was used to quantify RNA samples and these samples were submitted to 
Bionalyzer from Agilent Technologies (Santa Clara, CA) for determination of RNA quality. 
Cutoff for RNA integrity number (RIN) determined by the Bioanalyzer was 7.0. Reverse-
transcription reactions were carried out for 1 ug of total RNA for each sample using the High 
Capacity kit from Applied Byosystems (Foster City, CA). Primer/probe sets for the following 
NADPH oxidase components were purchased from Applied Biosystems (Foster City, CA): 
CYBB/Nox2, Nox4, CYBA/p22phox, NCF1/p47phox, NCF2/p67phox, NCF4/p40phox, Rac1, Nox1, 
Nox5, NOXA1, and NOXO1. Ribosomal gene 18-S was used as an endogenous loading control. 
The relative standard curve method was used to determine relative gene expression differences 
between normal myometrium and leiomyoma tissues. Briefly, a pool of samples was established 
to set up the standard curve for all assays. Every tested gene, including the endogenous control, 
had a standard curve along with the unknown samples within the same plate. Expression values 
for the target genes were normalized for 18-S gene expression. Expression values adjusted for 
the endogenous control were normalized by the average of normal myometrial tissue expression. 
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This approach allowed us to establish the value for normal myometrium as the base level control, 
which was set as 1, as well as to calculate a measurement of error. 
 
4.3.2 Effects of PKC on Erk activation 
Leiomyoma and normal myometrial cells were cultured in 60mm dishes until they 
reached 90% confluence. Cells were then switched to DMEM containing 0.5% fetal bovine 
serum (FBS) for 1 hour prior to adding treatments. Cells were treated with either 0, 200 nM or 
400 nM phorbol 12-myristate 13-acetate (PMA - P1585) from Sigma (St. Louis, MO) in DMEM 
containing 0.5% FBS for 15 minutes. To collect the cell lysates, warm Laemmli sample buffer 
was added directly to the cells, lysates were scraped off the dishes, and transferred to a 1.5 ml 
tubes. Lysates were heated at 95°C for 3 minutes and then frozen at -20°C. Lysates were later 
sonicated to shear genomic DNA and protein concentrations determined by BCA assay. 
Approximately 5 ug of protein for each sample were loaded onto SDS-PAGE gels and 
electrophoresis was performed. Protein transfers were performed overnight and successful 
transfer was checked by Ponceau staining. Membranes were blocked in 5% milk for 1 hour and 
primary rabbit anti-Erk1/2 (diluted at 1:1000) or mouse anti-phosphorylated Erk1/2 (diluted at 
1:2000) antibodies from Cell Signaling (Danvers, MA) were incubated in 3% BSA or 5% milk 
respectively, overnight at 4°C. HRP-conjugated horse anti-mouse IgG and HRP-conjugated goat 
anti-rabbit IgG antibodies, purchased from from Cell Signaling (Danvers, MA), were diluted at 
1:10000, and incubation was carried out at room temperature for 1 hour, followed by addition of 
chemiluminescence substrate to the membrane and X-ray film exposure and development. 
Experiments assessing the effects of PKC inhibition on PDGF-induced Erk activation 
were performed following a similar methodology with adaptations according to the specific 
  71 
treatment. Depletion of PKC was achieved by treating cells with the PKC inhibitor 
bisindolylmaleimide I (Bis - 203291) from EMD Chemiclas (Gibbstown, NJ) at 1 or 5 µM for 30 
minutes, followed by addition of DMEM containing 0.5% fetal bovine serum with or without 
PDGF (10 ng/ml) for 15 minutes. The positive control consisted of cells treated with PDGF 
without preexposure to Bis.  
 
4.3.3 Effects of PKC stimulation on ROS production 
Leiomyoma and normal myometrial cells were plated in IbiTreat µ-dishes (80136) from 
Ibidi (Munich, Germany) at an initial density of 2,000 cells per dish in phenol red free DMEM 
containing 10% serum and cultured until reaching 50% confluence. At this stage cells were 
transferred to DMEM containing 10% serum and transferred to an incubator at the imaging 
facility. Cells were washed 3 times in Dulbecco’s PBS and incubated with the oxidation sensitive 
dye carboxy-H2DCFDA for 15 minutes. Cells were then washed 2 times with DPBS and 
incubated with or without PMA or PDGF in DPBS for 15 minutes. PKC inhibition experiments 
involved 15 minutes of pre-treatment with the PKC inhibitors Bis or Go-6983 followed by PDGF 
treatment for 15 minutes in the presence of Bis (5 µM) or Go-6983 (5 µM). Cells exposed to 
PMA, Go-6983 or Bis only, in the absence of carboxy-H2DCFDA were used to control for each 
compound’s auto-fluorescence. After addition of growth factor or PMA cells were transferred to 
the fluorescence microscope and were kept in a chamber under controlled temperature and CO2 
concentration while images were captured. A change in fluorescent signal was interpreted as a 
change in ROS production. 
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4.3.4 Immunohistochemistry for p47phox 
Normal myometrial and leiomyoma tissues embedded in paraffin were sectioned to 5 µm 
thick sections. Following deparaffinization and dehydration, antigen retrieval was performed by 
boiling slides in citrate buffer for 30 minutes at 50% power in the microwave. After cooling 
down the slides to room temperature the quenching of endogenous peroxidase activity was 
performed by incubating samples in a solution of 0.3% hydrogen peroxide in methanol for 15 
minutes. Samples were then blocked in 1.5% goat serum (PBS/0.05% Tween-20) for 1 hour and 
primary antibody incubation with rabbit anti-human p47phox antibody (ab63361) from Abcam 
(Cambridge, MA) diluted at 1:400, was performed overnight at 4°C. The Vectastain Elite ABC 
Kit from Vector Laboratories (Burlingame, CA) was used for immunostaining detection. 
Following overnight incubation with the primary antibody samples were incubated with 
biotinylated anti-rabbit secondary antibody for 1 hour at room temperature. ABC reagent, 
containing avidin and biotinylated horseradish peroxidase H was then prepared and incubated 
with slides for 30 minutes. Samples were then exposed to DAB and the colorimetric reaction was 
stopped in tap water. Hematoxylin counterstaining was performed followed by dehydration, 
clearing and mounting of slides. 
 
4.3.5 Immunofluorescent detection of phosphorylated p47phox after treatment with PDGF 
Leiomyoma and normal myometrial cells were plated in ibiTreat µ-dishes (80136) from 
Ibidi (Munich, Germany) at 6,000 cells per well in phenol red free DMEM/10% serum. Cells 
were grown until 50% confluence and then cultured in DMEM containing 0.5% fetal bovine 
serum (FBS) for one hour. Stimulation with PDGF (10 ng/mL) was performed in DMEM 
containing 0.5% fetal bovine serum (FBS) for 15 or 30 minutes. After treatment cells were rinsed 
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3 times with Dulbecco’s PBS, and fixed with 4% paraformaldehyde (15710) from Electron 
Microscopy Sciences (Hatfield, PA) for 25 minutes at room temperature. Following fixation cells 
were washed 3 times with DPBS and permeabilized in 0.2% Triton X-100 for 10 minutes. 
Blocking of non-specific binding was performed with Image-iT FX signal enhancer (I36933) 
from Invitrogen (Carlsbad, CA) for one hour. Primary antibody incubation with rabbit anti-
phospho-p47phox (ab74095) from Abcam (Cambridge, MA) diluted at 1:400 was performed 
overnight at 4°C in DPBS containing 0.2% BSA and 0.05% Tween 20. Secondary antibody, 
Alexa Fluor 546 goat anti-rabbit IgG (A11035) from Invitrogen (Carlsbad, CA) was diluted at 
1:100, and incubation was performed at room temperature for one hour using the same buffer as 
for primary antibody incubation. DAPI (D3571) from Invitrogen (Carlsbad, CA) was added to 
cells at 5µg/ml prior to mounting the slides and incubated for 10 minutes. Dishes were washed 
once with DPBS and ProLong Gold antifade reagent (P36930) from Invitrogen (Carlsbad, CA) 
was used to mount slides. Slides were then incubated overnight at room temperature and stored 
at 4°C for subsequent imaging. Refer to APPENDIX G for a more detailed immunofluorescence 
protocol and to APPENDIX H to a detailed step-by-step procedure on imaging 
immunofluorescent images. 
 
4.3.6 Immunoblotting for detection of p47phox phosphorylation 
Cell culture conditions, serum starvation, cell lysate collection and western blotting 
procedure followed the steps described in item 4.3.2, with the exception of the amount of total 
protein loaded for p47phox immunodetection, which was around 30 µg. To determine the time-
course of p47phox phosphorylation, leiomyoma and normal myometrial cells were exposed to 
either PDGF (10 ng/ml) or PMA (1 µM) for 5, 10 or 30 minutes and cell lysates were collected. 
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Next, experiments were performed to assess the effects of PKC inhibitors on PDGF and PMA-
induced p47phox phosphorylation. Cells were pretreated with either 5 µM of Go-6983 (G1918) 
from Sigma (St. Louis, MO), 5 µM of Bis or DMEM only (0.5% FBS) for 15 minutes, then 
exposed to either PDGF (10 ng/ml) or PMA (1 µM) for 5 minutes in the presence or absence of 
the inhibitors. Cell lysates were collected at the end of the treatment periods. Immunodetection 
of the phosphorylated form of p47phox was achieved by incubating membranes with a rabbit anti-
human phosphorylated-p47phox polyclonal antibody (ab74095) from Abcam (Cambridge, MA) 
diluted in 5% BSA/TBS-T for 90 minutes at room temperature. Membranes were then stripped at 
room temperature for 20 minutes and reprobed with a rabbit anti-human p47phox polyclonal 
antibody (BS1846) from Bioworld (Minneapolis, MN) at room temperature for 90 minutes. 
 
4.3.7 Sucrose gradient ultra-centrifugation for localization of p47phox in lipid rafts 
Leiomyoma cells were plated into 100 cm plastic dishes at approximately 600,000 
cells/dish and grown to 90% confluence. After reaching 90% confluence cells were serum 
starved for 24 hours and then treated with PDGF (10ng/ml), EGF (50ng/ml) or DMEM/0.5% 
FBS (Control) for 3 minutes. Cells were washed with PBS/5 mM EDTA and placed on ice. Cell 
scrapers were used to remove cells from the dishes and cell suspensions collected into 50 ml 
conical tubes and later centrifuged at 1,000 RPM for 5 minutes at 4°C. Supernatants were 
removed and 500 µl ice-cold lysis buffer added to ressuspend cell pellets followed by incubation 
on ice for 15 minutes. Sucrose gradients were obtained by adding 500 µl of ice-cold 80% sucrose 
buffer to yield a solution of cell lysate in 40% sucrose buffer. This solution was transferred to 
ultracentrifuge tubes and 2.5 ml of 35% sucrose was layered on top of the 40% solution, 
followed by addition of 5% sucrose buffer (500 µl) on top of the 35% solution. Cell lysates on 
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sucrose gradients were centrifuged at 45,000 RPM for 12 hours at 4°C. TX-100 sucrose gradient 
fractions of 500 µl were collected for a total of 8 fractions. Warm 1X Laemmli sample buffer 
(LSB) was added to the insoluble pellet, fractions mixed to 4X LSB, and then heated to 95°C for 
5 minutes prior to loading onto SDS-PAGE gels. Refer to APPENDIX I for a more detailed 
protocol. Densitometry analysis was performed to quantify the proportion of p47phox that was 
present in lipid raft fractions versus total p47phox. The average proportion of p47phox present in 
lipid rafts was compared between LSMCs exposed to either EGF or PDGF and untreated cells. 
To determine whether the increase in p47phox in lipid rafts after growth factor treatment was 
statistically significant a paired one-tailed t-test was performed. 
 
4.4 RESULTS 
4.4.1 NADPH oxidase complex expression in leiomyoma and myometrial tissues 
Quantitative RT-PCR performed on RNA from matched pairs of leiomyoma and normal 
myometrial tissues detected the expression of the majority of the NADPH oxidase complex 
components. The average cycle threshold (Ct) values across all tested samples are indicators of 
how abundant the expression of a given gene is. The results presented in Table 1 show the 
average Ct values for all genes tested. As a preliminary assessment of the data one can compare 
average Ct values among isoforms and estimate which isoforms are more abundant and 
potentially more relevant in the cell types being studied. For example, of the Nox enzymes tested 
(Nox1, Nox2, Nox3, Nox4, and Nox5; DUOX1 and DUOX2 were not tested) Nox2 (gp91phox) 
and Nox4 were the most abundant. NOXA1 and NOXO1 were almost undetectable in these 
tissues, suggesting that their homologues, p67phox and p47phox, respectively, are more relevant 
biologically.  
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Analysis of relative gene expression between leiomyoma and normal myometrial tissues 
within matched pairs showed no differential expression for most of the subunits with the 
exception of two genes that showed overall reduced expression in leiomyoma tumors (Figure 
18). However, further analysis involving examination of gene expression levels in a patient-
specific manner revealed an interesting pattern that can be observed in Table 2. When analyzing 
the expression of the 7 NADPH subunits present in the tested tissues I observed that out of the 10 
matched pairs, three of these pairs showed increased expression of at least 4 of the subunits in 
leiomyoma tissues.  Findings of this study indicate significant tumor heterogeneity in regards to 
the pattern of expression of the NADPH oxidase subunits, suggesting that some NADPH oxidase 
subunits might be involved in the pathogenesis of a subgroup of leiomyoma tumors.  
 
4.4.2 Effects of PKC on ROS production 
Activation of the NADPH oxidase complex in some cell types is triggered by serine 
phosphorylation of the cytosolic component p47phox. Phosphorylation of p47phox induces its 
conformational change that leads to unmasking of a protein domain that then interacts with 
membrane-bound p22phox, targeting p47phox and the rest of the cytosolic complex to the cell 
membrane leading ultimately to ROS production. Based on previous studies in other cell types I 
hypothesize that PKC is the kinase responsible for phosphorylating p47phox and driving NADPH 
oxidase activation. To assess whether alterations in PKC activity would affect ROS production 
directly, I used the cell-permeant indicator for ROS, carboxy-H2DCFDA. Treatment with PDGF 
was used as a positive control because I have used it previously as a potent trigger of ROS 
production. Whereas exposure of cells to DPBS alone resulted only in a basal fluorescence 
signal, treatment with PMA at 400 nM for 15 minutes induced a noticeable increase in 
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fluorescence, indicating increased ROS production (Figure 19). To test the involvement of PKC 
in PDGF or PMA-induced ROS production I used the PKC inhibitor Bis as a pre-treatment prior 
to exposing cells to PDGF. Surprisingly, after PDGF treatment in the presence of Bis there was a 
significant increase in the fluorescence signal (Figure 19). I determined that the increased signal 
was due to autofluorescence of the Bis compound (APPENDIX J). To overcome this technical 
difficulty I used a different compound also known to inhibit PKC activity called Go-6983. The 
second PKC inhibitor tested also showed background fluorescence above that of DPBS-only 
treated cells (APPENDIX J). However, the fluorescence background induced by Go-6983 was 
below the signal observed in PDGF and PMA-treated cells (APPENDIX J). Furthermore, the 
pattern of fluorescent signal observed in cells exposed to Go-6983 or Bis only, which consisted 
of highly fluorescent spots (APPENDIX J), was different than the smooth and evenly distributed 
signal observed in PDGF or PMA-treated cells, as shown in Figures 20 and 21. The increase in 
ROS production induced by either PDGF or PMA was not observed in the presence of the PKC 
inhibitor, Go-6983, indicating that PKC activity is necessary for the PDGF or PMA-induced 
increase in ROS production in leiomyoma and normal myometrial cells. 
 
4.4.3 Effects of PKC on Erk activation 
To continue testing the hypothesis that ROS are necessary for the Erk1/2 signaling 
pathway, the next goal was to determine whether manipulations of PKC activity, which I showed 
to regulate ROS production, would interfere the activation of the downstream effector Erk1/2. I 
therefore tested whether induction of PKC by the phorbol ester PMA would alter 
phosphorylation of Erk1/2, or whether inhibition of PKC would reduce Erk1/2 phosphorylation 
induced by PDGF. PMA treatment alone for 15 minutes was sufficient to induce Erk1/2 
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phosphorylation while pre-treatment with the PKC inhibitor Bis reduced PDGF-induced Erk1/2 
activation (Figure 22). 
 
4.4.4 Immunohistochemistry for p47phox 
The results from the gene expression analysis confirmed the presence of the Nox2, 
p22phox, p47phox, p67phox and Rac1 subunits in leiomyoma tumors as well as in normal 
myometrium. I hypothesize that the activation of the NADPH oxidase complex is triggered upon 
phosphorylation of p47phox, leading to targeting of this protein with the other cytosolic 
components, p67phox, p40phox and Rac1, to the cell membrane. I decided to focus the subsequent 
analysis on p47phox because of the availability of an antibody to this subunit and the necessity of 
phosphorylation of this subunit for membrane targeting. Immunohistochemistry analysis of 
leiomyoma and normal myometrial tissues detected cytosolic p47phox protein expression in SMCs 
as well as in the endometrial epithelium and endothelial cells (Figure 23). Interestingly, the 
majority of the endometrial epithelial cells showed nuclear staining, whereas only a fraction of 
the leiomyoma and myometrial SMCs had nuclear p47phox expession. When comparing the 
intensity of cytoplasmic and nuclear staining between paired (from the same patient) leiomyoma 
and myometrial tissues, overall cytoplasmic staining did not appear to be different between 
leiomyoma and myometrial tissue, whereas nuclear staining was slightly more intense in 
leiomyoma than in myometrial tissue. The relevance of the nuclear localization as well as the 
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4.4.5 Immunofluorescent detection of p47phox phosphorylation 
An alternative way of testing the involvement of p47phox as a primary player in PDGF-
induced ROS production was to assess the level of p47phox phosphorylation in response to PDGF. 
The approach used to test the above hypothesis involved immunofluorescence detection of the 
phosphorylated form of p47phox protein in cultured cells. Immunofluorescence results showed a 
modest increase in the signal for phosphorylated p47phox in both cell types, but this was more 
prevalent in leiomyoma SMCs (Figure 24). The pattern of imunostaining showed an 
accumulation of cytoplasmic phosphorylated p47phox in a punctate manner around the nucleus, as 
well as nuclear staining. Staining was more pronounced at 30 minutes after PDGF induction 
versus 15 minutes. There was also phosphorylated p47phox staining of cell projections that 
became enriched over-time. Interestingly, there was also some indication that leiomyoma cells 
showed a higher basal level of p47phox phosphorylation than normal myometrial cells.  
 
4.4.6 Immunoblot detection of p47phox phosphorylation 
Immunodetection by immunoblotting was used to determine whether p47phox 
phosphorylation is a downstream event following the activation of leiomyoma and normal 
myometrial cells by PDGF, and whether p47phox phosphorylation is regulated by PKC. I 
observed that the basal phosphorylation levels of p47phox were high in cells that were exposed to 
DMEM containing 0.5% FBS only. There was no further increase above basal levels of p47phox 
phosphorylation after either PDGF or PMA stimulation for 5, 10 or 30 minutes (Figures 25 A 
and B). To test whether PKC inhibitors would alter p47phox phosphorylation levels, I pre-treated 
both leiomyoma and normal myometrial cells with the PKC inhibitors Go-6983 or Bis for 15 
minutes and then exposed them to PDGF or PMA in the presence or absence of the inhibitors. 
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There was no difference in the phosphorylation levels of p47phox between cells exposed to PDGF 
or PMA in absence or presence of PKC inhibitors (Figures 26 A and B). No differential response 
was observed between leiomyoma and normal myometrial cells.  
 
4.4.7 Localization of p47phox in lipid rafts 
Lipid rafts are specialized plasma membrane microdomains that can bring signaling 
molecules together or keep them apart. In many signaling pathways the proximity between 
molecules is sufficient to trigger their interaction leading to activation or inhibition of signaling 
activity. I hypothesized that during the activation of the NADPH oxidase complex in SMCs the 
complex may be targeted to lipid rafts where its transient and controlled ROS production would 
be in close proximity to potential target molecules facilitating the role of ROS as a signaling 
molecule. I used sucrose gradients and ultra-centrifugation to separate lipid raft fractions from 
leiomyoma SMC lysates isolated with TX-100 detergent. Caveolin-1 detection by immunoblot 
indicated that the technique was accurately separating the lipid raft fractions (Figure 27A).  
Results suggest that in response to both PDGF and EGF there was an enrichment of p47phox 
protein into the lipid raft fractions (Figure 27B) in comparison to untreated cells. However, 
densitometry analysis showed that PDGF treatment induces an increase in the proportion of total 
p47phox that is present in lipid rafts (p=0.051), whereas EGF did not show statistically significant 
changes. These data suggest that lipid rafts may play an important role in the mechanism of 
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4.5 DISCUSSION 
The goals of this study were to characterize the expression pattern of NADPH oxidase 
complex components in leiomyoma tumors in comparison to the normal myometrium expression 
pattern, determine the mechanism leading to the activation of this complex by PDGF, and assess 
the participation of PKC in this process. This manuscript is the first to report the expression of 
specific NADPH oxidase components in leiomyoma SMCs, and the first to suggest that p47phox 
may be one of the critical cytosolic subunits of NADPH oxidase in normal myometrial and 
leiomyoma SMCs. In addition, I have also demonstrated that translocation of p47phox into lipid 
rafts occurs in response to PDGF, and the involvement of PKC as a mediator of Erk activation by 
PDGF as well as an inducer of ROS production. 
The NADPH oxidase complex and its components have been identified in a variety of 
tissues, cell types, and species. Ishikawa et al. (1984) reported the existence of a hydrogen 
peroxide-producing NADPH oxidase in the endometrial epithelium of rats [168]. Jain et al. 
(2000) demonstrated NADPH oxidase-dependent superoxide production in the mouse uterus, 
which increased at pro-estrus and during the pre-implantation period in pregnant mice [169]. 
Expression of the Nox proteins Nox1, Nox2, Nox4, Nox5, Duox1 and Duox2 has been reported 
in the human uterus [11, 137, 170]. Cui et al (2009) reported by non-quantitative RT-PCR the 
expression of p22phox, p47phox, p67phox, p40phox, Rac1 and Rac2 in the human uterus, and Nox1, 
Nox2, Nox4, Nox5, and Duox1 in an immortalized human myometrial SMC line [170]. Results 
obtained in the present study of gene expression are similar to those of Cui and coworkers and 
suggest that p47phox and p67phox are more relevant than their isoforms with negligible expression, 
NOXO1 and NOXA1, respectively. With respect to the Nox proteins results indicated that Nox4 
also had high levels of expression similar to the data reported by Cui and coworkers. Nox2 was 
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less abundant than Nox1 in this study, whereas Cui et al. reported an opposite trend of expression 
between the two subunits. Some of the differences may be attributed to the different techniques 
used to assess gene expression, qRT-PCR in present work and non-quantitative RT-PCR by Cui 
et al (2009) [170]. 
Immunohistochemistry results showed that p47phox protein expression in smooth muscle 
cells of leiomyoma and myometrial tissues is cytoplasmic as did immunofluorescence staining of 
cultured leiomyoma and myometrial cells. In both cases, although cytosolic staining was 
detected in smooth muscle cells, strong nuclear staining was also observed in many SMCs as 
well as in all endometrial epithelial cells. Nuclear localization of p47phox has been reported by 
Mofarrahi et al (2008), who observed this pattern in 30% of human myoblast cells transfected 
with the fusion protein cyan-fluorescent protein-p47phox [171]. The multiple protein binding 
domains present in p47phox confirm its function as an adapter protein. Gu et al. (2003) also 
observed nuclear localization of p47phox as well as an interaction between p47phox and RelA, a 
member of the NFκB complex that has a nuclear localization sequence [172]. These authors 
went further to determine the specificity and functional importance of this interaction and 
demonstrated its effects on RelA phosphorylation and activation leading to NFκB activation 
[172]. Colocalization of NADPH oxidase subunits in lipid rafts reported by Jin et al. (2008) 
showed a pattern of expression consisting of punctate staining clustered around the nucleus of 
some cells [173]. Confocal images from Jin et al. (2008) clearly showed that although the signal 
was stronger close to nucleus it was not present within the nucleus. Although the images from 
the present study were not taken under a confocal microscope the pattern observed suggests 
cytoplasmic punctate staining as well as nuclear staining [173]. This unexpected nuclear 
localization of the cytosolic p47phox subunit in leiomyoma and myometrial SMCs suggests an 
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interaction with another protein or complex of proteins, as p47phox itself does not have a nuclear 
localization sequence. Mofarrahi et al (2008) also observed that p47phox protein expression 
declined over-time as myoblast cells differentiate into myotubes [171]. Taken together with the 
findings in the present work, which showed strong p47phox nuclear expression in endometrial 
epithelial cells and some SMCs as well as more intense nuclear staining in leiomyoma SMCs in 
comparison to myometrial SMCs, I speculate that p47phox nuclear localization may be related to 
the state of differentiation of cells, or whether cells are actively proliferating. 
I know from my previous work that PDGF induces ROS production in leiomyoma and 
myometrial SMCs, and that this ROS production is derived from the NADPH oxidase complex 
[165]. My next goal was to determine more specifically how PDGF might be leading to the 
activation of NADPH oxidase. In human monocytes PKC δ was identified as the PKC isoform 
responsible for p47phox phosphorylation and translocation to the cell membrane [174]. 
Additionally, in human neutrophils PKCs α, βII, ζ, and δ were able to phosphorylate p47phox and 
induce its translocation [175]. Catarzi et al. (2005) showed that in NIH3T3 fibroblasts PDGF-
induced ROS production is dependent on the NADPH oxidase complex, PKC and PI3K [113]. 
My working hypothesis was that PDGF would activate the NADPH oxidase complex by 
inducing phosphorylation of p47phox, and that PKC was the kinase involved in activation of 
NADPH oxidase. The results of the immunofluorescence studies agree with previously reported 
results indicating that PDGF induces a subtle increase in p47phox phosphorylation which was 
more pronounced in leiomyoma than in myometrial SMCs. However, immunodetection of the 
phosphorylated form of p47phox by immunoblotting did not show an increase in the levels of 
phosphorylated p47phox in cells treated with PDGF or PMA. Furthermore, the PKC inhibitors Bis 
and Go-6983 had no effect on p47phox phosphorylation in PDGF or PMA-exposed SMCs. 
  84 
Immunoblotting is a technique more likely to provide an accurate quantitation of changes in 
protein phosphorylation levels in comparison to immunofluorescence. Thus, the discrepancy 
between the results might be explained by the different techniques utilized. Furthermore, it is 
possible that the apparent increase in p47phox phosphorylation observed by immunofluorescence 
might in fact indicate a redistribution and accumulation of phosphorylated p47phox in subcellular 
compartments in response to PDGF, as observed by a distinctly higher fluorescent signal at the 
edges of cell projections in PDGF-treated cells. This observation is in agreement with the lipid 
raft data, which indicates that PDGF induces an enrichment of p47phox into lipid rafts. 
The observation that phosphorylated p47phox is present in unstimulated cells suggests the 
existence of a preassembled NADPH complex, because p47phox must be phosphorylated in order 
to interact with the other subunits. Li et al. (2002) reported similar findings. These authors 
determined that the NADPH oxidase complex is found preassembled in the cytosol and that 
unstimulated endothelial cells have detectable basal intracellular ROS production [134]. Overall, 
it also appears that p47phox phosphorylation staining is higher in leiomyoma SMCs than in 
myometrial SMCs. Findings of this study go further and indicate that p47phox phosphorylation is 
not involved with PDGF or PMA-induced ROS production. Although PDGF and PMA induce 
ROS production, they fail to induce p47phox phosphorylation, suggesting that another NADPH 
oxidase subunit, regulated by PKC, may involved in the PDGF-induced NADPH oxidase 
activation. Other two potential candidates as targets of PKC and reglulators of ROS production 
in leiomyoma and myometrial SMCs are p40phox and p67phox, which have been implicated in 
NADPH oxidase activation in neutrophils and endothelial cells in response to PDGF and PMA, 
respectively [176, 177]. In addition, I also showed that manipulation of PKC activity alters ROS 
production, a marker of NADPH oxidase activity, and Erk phosphorylation, a downstream 
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marker of the PDGF-induced proliferation. Erk activation by PDGF has been shown to be 
dependent on ROS production and ROS alone are sufficient to induce Erk activation in 
leiomyoma SMCs [165]. 
As part of the characterization of the NADPH oxidase complex and its mechanism of 
action in uterine SMCs, I further hypothesized that upon p47phox activation its translocation to the 
plasma membrane would involve localization in lipid rafts. The involvement of lipid rafts in the 
assembly of signaling platforms, specifically the ROS-generating NADPH oxidase has been 
reported. In macrophages and promyelocytic leukemia cells the membrane-bound components of 
the NADPH oxidase complex are present in lipid rafts as well as the cytosolic components 
p47phox and p67phox are present in lipid rafts which become more enriched upon stimulation of 
PKC by PMA [178]. Jin et al. (2008) reported that in bovine endothelial cells endostatin induces 
enrichment of Nox2 and p47phox into lipid rafts and leads to increased activity of the complex. In 
these studies I also observed an enrichment of p47phox protein in response to exposure to PDGF 
into lipid raft fractions as determined by TX-100 sucrose gradient centrifugation. In VEGF-
stimulated migration of endothelial cells, targeting of the NADPH oxidase complex to lipid rafts 
leads to a series of localized events necessary for establishment of the focal complexes on the 
lamellipodial leading edge of migrating cells. Additionally, VEGF-R2 localization at the focal 
complexes, which is necessary for proper activation of VEGF-induced ROS-dependent 
angiogenic signaling, depends on phosphorylation of the lipid raft component caveolin-1 
(reviewed by [166]). Interestingly, I observed a clear pattern of enrichment of phosphorylated 
p47phox staining at the edge of the cell membranes of SMCs showing long projections in the 
immunofluorescence experiments. Similarly, Gu et al. (2003) observed colocalization of p47phox 
and RelA on some of these projections, identified by the authors as focal protrusions [172]. In 
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the present experiments cells were fixed for immunostaining at approximately 50% confluence 
and it was evident that a large number of relatively small cells were emitting projections 
suggesting cell migration. Whether this observed pattern was due to localization of 
phosphorylated p47phox in lipid rafts and whether this mechanism is relevant for cell migration in 
uterine SMCs remains to be tested. 
In summary, the NADPH oxidase complex is present in normal human myometrial and 
leiomyoma tissues and the in vitro data support the involvement of p47phox in the activation of 
the complex, potentially through its translocation into lipid rafts in response to PDGF as well as 
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Rac1 26.77  
Table 1. Average cycle threshold (Ct) values of all tested (myometrium and leiomyoma tissue) 
samples for each tested member of the NADPH oxidase complex. Higher average Ct values are 
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Figure 18. Relative fold difference in gene expression between normal myometrium and 
leiomyoma tissues measured by qRT-PCR. Asterisks indicate significant difference in gene 
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Genes
Patients p47phox p22phox Rac1 p40phox Nox2 p67phox Nox4
620 0.38 0.60 0.61 1.16 0.88 0.49 1.82
1378 0.39 0.65 0.48 0.46 0.40 0.42 0.96
2276 0.30 0.62 0.46 0.44 0.38 0.33 1.15
2699 1.93 1.04 0.90 1.94 6.35 1.68 3.78
3368 0.34 1.17 0.34 0.63 0.43 0.30 1.44
3644 0.34 0.66 0.67 0.59 0.44 0.47 0.92
5027 1.03 0.93 1.67 1.30 1.54 1.11 1.39
5339 0.27 0.29 0.61 0.32 0.22 0.25 0.88
8011 0.28 4.10 0.76 0.41 0.58 0.66 0.87
9912 1.71 0.93 0.95 1.60 2.96 2.02 1.47  
Table 2. Relative fold difference of gene expression between normal myometrium and 
leiomyoma tissues within patient matched tissue pairs. Numbers under gene columns represent 
ratio of expression with myometrial gene expression as the normalizer. Patient numbers 
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Figure 19. ROS production in response to PDGF, PMA and PDGF + Bis. Detection of ROS 
production by oxidation-sensitive dye carboxy-H2DCFDA in leiomyoma and myometrial SMCs. 
Cell were treated with DPBS (negative control – top images) in the presence or absence of PMA 
(400 nM) or PDGF (10 ng/ml) for 15 minutes. Bottom images (Bis) refer to cells pre-treated with 
Bis (5 µM) for 15 minutes, followed by PDGF treatment in the presence of Bis for 15 minutes. 
Green signal indicates ROS production. Images were captured at 400X magnification. 
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Figure 20. Effects of manipulations of PKC activity in ROS production. Detection of ROS 
production by oxidation-sensitive dye carboxy-H2DCFDA in leiomyoma and myometrial SMCs. 
Cell were treated with DPBS (negative control) and PMA (1 µM) for 15 minutes. Inhibition of 
PKC was attained by pre-treating cells with Go-6983 (5 µM) for 15 minutes followed by PMA 
treatment in the presence of Go-6983. Green signal indicates ROS production. Images were 
captured at 400X magnification. 
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Figure 21. Involvement of PKC in PDGF-induced ROS production. Detection of ROS 
production by oxidation-sensitive dye carboxy-H2DCFDA in leiomyoma and myometrial SMCs. 
Cell were treated with DPBS (negative control) and PDGF (10 ng/ml) for 15 minutes. Inhibition 
of PKC was attained by pre-treating cells with Go-6983 (5 µM) for 15 minutes followed by 
PDGF treatment in the presence of Go-6983. Green signal indicates ROS production. Images 
were captured at 400X magnification. 
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Figure 22. Involvement of PKC in Erk activation. Immunoblots for phosphorylated Erk (pErk) 
and total Erk protein (tErk-loading control) are shown. A) Cells were stimulated with or without 
PMA for 15 minutes. B) Cells were pre-treated with or without Bis for 30 minutes, followed by 
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Figure 23. Immunohistochemistry for p47phox. Representative cross sections of leiomyoma (A 
and B), myometrial (C and D) and myometrial+endometrial tissue (E and F). Images A, C and E 
are represent 400X magnification, and images B, D and F represent 630X magnification. Black 
arrows indicate bundles of smooth muscle cells with cytosolic staining. White arrows indicate 
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Figure 24. Immunofluorescence detection of phosphorylated p47phox in leiomyoma and 
myometrial SMCs. Immunodetection of the phosphorylated form of p47phox as a sign of NADPH 
oxidase activation in response to PDGF over time. White triangles indicate stronger staining at 
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Figure 25. Immunoblotting detection of phosphorylated p47phox in leiomyoma and myometrial 
SMCs – Response to PDGF and PMA. Time-course of p47phox phosphorylation in response to 
PDGF (10 ng/ml) and PMA (1 µM) in (A) leiomyoma and (B) myometrial SMCs. Letter C 
indicates cells treated with DMEM/0.5% FBS at time-point zero, whereas other groups included 
cells treated with either PDGF or PMA for 5, 10 and 30 minutes. 
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Figure 26. Immunoblotting detection of phosphorylated p47phox in leiomyoma and myometrial 
SMCs – Involvemente of PKC. p47phox phosphorylation in response to (A) PDGF (10 ng/ml) and 
(B) PMA (1 µM) in the absence or presence of 5 µM of Go-6983 (Go) or 5 µM of Bis. Letter C 
indicates cells treated with DMEM/0.5% FBS for 5 minutes, whereas other groups included cells 
treated with either PDGF or PMA for 5 minutes. 
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Figure 27. Immunodetection of p47phox in lipid raft fractions by sucrose gradient centrifugation. 
A) Immunoblot for caveolin-1 (CAV-1) as a marker for lipid rat fractions. Insoluble pellet (INS). 
B) Immunoblot for p47phox on TX-100 sucrose gradient fractions of leiomyoma cells treated with 
EGF or PDGF for 3 minutes and unstimulated. Boxes on each blot indicate lipid raft fractions. 
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CHAPTER 5 
ROS-DEPENDENT ACTIVATION OF PROTEIN TYROSINE PHOSPHATASES AND 
THEIR INVOLVEMENT IN THE PROLIFERATIVE PATHWAY OF NORMAL 
MYOMETRIAL AND LEIOMYOMA SMOOTH MUSCLE CELLS 
 
5.1 ABSTRACT 
My previous work indicates that NADPH oxidase-derived reactive oxygen species (ROS) 
play an important role in the PDGF proliferative pathway in leiomyoma smooth muscle cells 
(SMCs). ROS can act as signaling molecules by modifying specific targets such as protein 
tyrosine phosphatases (PTPases). My aim in this study was to determine whether ROS could 
affect PTPase activity and whether changes in PTPase activity might regulate proliferation of 
myometrial and leiomyoma SMCs through the PDGF signaling pathway by altering PDGF 
receptor (PDGF-R) phosphorylation. I used primary cultures of normal myometrial and 
leiomyoma smooth muscle cells as the experimental model. PTPase activity in cell lysates of 
treated cells was measured using a colorimetric tyrosine phosphatase assay. The PTPase inhibitor 
sodium orthovanadate was used to assess the involvement of these enzymes in the cellular 
responses tested. Cell proliferation was measured by tritiated thymidine incorporation assays, 
and phosphorylation of PDGF-R was assessed by immunoblotting. My results show that an 
exogenous source of ROS, hydrogen peroxide, was sufficient to inhibit PTPase activity in 
leiomyoma SMCs, but not in myometrial cells. No effect of PDGF on PTPase activity was 
observed in either cell type. Inhibition of PTPase activity by low concentrations of sodium 
orthovanadate led to an induction of cell proliferation, with higher concentrations reducing 
proliferation. Interestingly, leiomyoma SMCs were sensitive to much lower concentrations of 
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sodium orthovanadate than myometrial SMCs. No effect of PTPase inhibition by sodium 
orthovanadate on basal PDGF-R phosphorylation was observed. In conclusion, PTPase activity 




Leiomyoma tumors are benign neoplasms that arise from uterine smooth muscle cells that 
proliferate excessively and are characterized by a change in the composition and deposition of 
extracellular matrix proteins (i.e., overproduction of collagens type I and III) [2, 32, 33]. PDGF 
and PDGF receptors are also more highly expressed in leiomyoma tumors than in normal 
myometrium and their expression fluctuates throughout the menstrual cycle [179]. 
Estrogen stimulates PDGF production and secretion in leiomyoma cells [60]. Of interest 
to our laboratory is the fact that PDGF induces ROS production in a number of cell types, 
including leiomyoma SMCs, and that ROS are necessary for PDGF-induced DNA synthesis [17, 
165]. In addition, ROS production is also necessary for PDGF-induced Erk phosphorylation in 
human leiomyoma SMCs and ELT-3 rat leiomyoma SMCs [165, 180]. 
ROS cannot alter the phosphorylation status of proteins to directly modulate the 
activation of downstream effectors, however numerous families of proteins have amino acid 
residues that are sensitive to oxidation. Protein tyrosine phosphatases are known targets of ROS 
due to a cysteine residue that is sensitive to oxidation rendering the enzyme inactive. The 
oxidized residue is stable however the reaction is reversible indicating that it can be regulated by 
post-translational modifications by ROS  [15, 143]. It has been shown that Insulin or PDGF 
treatment leads to inactivation of PTPases, and more recently that NADPH oxidase-derived ROS 
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are responsible for inactivating PTPases [143-146]. Moreover, PTPase activation is associated 
with decreased activation of downstream effectors, and PTPase inactivation appears to be 
necessary to achieve proper tyrosine phosphorylation levels [18, 144, 145]. Further evidence for 
the importance of the oxidation mechanism for controlling PTPase activity comes from studies 
showing that suppression of hydrogen peroxide production by inhibition of superoxide 
desmutase 1 (SOD1) protects PTPases from inactivation and reduces growth factor-induced Erk 
phosphorylation [181]. In addition, enhanced glutaredoxin expression maintains activation of 
low molecular weight PTPase (LMW-PTP) and suppresses PDGF-induced cell proliferation by 
reducing phosphorylation of PDGF-Rβ [21]. 
One of the aims of my work was to determine more specifically some potential 
downstream targets of ROS action that could relate to the main hypothesis I are testing, which is 
that ROS are necessary components of the proliferative pathways controlled by PDGF. Based on 
results obtained by our group and other evidence from the literature I propose that PTPases are 
regulated by ROS and that modulation of PTPase activity alters cell proliferation in leiomyoma 
and myometrial SMCs. 
 
5.3 MATERIAL AND METHODS 
5.3.1 Effects of H2O2 and PDGF on PTPase activity 
Leiomyoma and normal myometrial cells were cultured in 60 mm dishes at 150,000 cells 
per dish until reaching 90% confluence. Cells were then cultured in DMEM containing 0.5% 
fetal bovine serum for 1 hour and treated with either PDGF (10 ng/ml) for either 15 or 30 
minutes, or with H2O2 at 10 or 100 µM for 15 minutes. After treatment cells were washed in ice-
cold PBS once, and ice-cold lysis buffer (50 mM Tris, pH 5.5, 100 µM EDTA, 100 µM EGTA, 
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0.5% TX-100) plus protease inhibitors was added. Cells were incubated for 10 minutes at 4°C in 
a belly dancer rocker and subsequently scraped off of the dish and transferred to a 1.5 ml tube. A 
tyrosine phosphatase assay system from Promega (Madison, WI) was used to determine tyrosine 
phosphatase activity in cell LSMCs and MSMCs lysates. Assays were performed according to 
the manufacturer’s protocol. Briefly, cell lysates were cleared by ultra-centrifugation at 100,000 
x g for 30 minutes at 4°C. To remove free phosphate from the cell lysates, samples were passed 
through a Sephadex G25 column and spun at 600 x g for 6 minutes. Protein concentrations were 
determined by BCA assay and 2.5 µg of protein were used for the tyrosine phosphatase assay. 
Cell lysates were first incubated with the substrate, a tyrosine phosphopeptide at 100 µM final 
concentration with the following sequence: END(pY)INASL, for 15 minutes in 96 well plates 
and an acidic dye solution was then added to stop the reaction as well as to react with free 
phosphate and allow quantitation of phosphatase activity. Dye incubation was carried out for 30 
minutes at room temperature and plates were then read at 590 nm on a plate reader. Appropriate 
standards for the standard curve were prepared by diluting 1 mM phosphate standard in 
phosphate-free water, and added to 1X reaction buffer in a 50 µl final volume. 
 
5.3.2 Effects of protein tyrosine phosphatase inhibitor, sodium orthovanadate, on cell 
proliferation 
Leiomyoma and normal myometrial cells were cultured in 96 well plates at 6,000 cells 
per well in DMEM containing 10% serum until reaching 90% confluence. Cells were then 
cultured in DMEM containing 0.5% FBS for 2 days and exposed to treatment. Tritiated 
thymidine was added during the last 24 hours of treatment. Treatments consisted of sodium 
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orthovanadate at 0.6, 1.25, 2.5, 5, 10, 20, 40, 80, and 160 nM for 48 hours followed by cell 
harvest and assessment of the DNA synthesis. 
 
5.3.3 Effects of protein tyrosine phosphatase inhibitor, sodium orthovanadate, on PDGF-R 
phosphorylation 
Leiomyoma and normal myometrial cells were cultured in 60mm dishes at 150,000 cells 
per dish in DMEM containing 10% serum until reaching 90% confluence. Cells were then 
cultured in DMEM containing 0.5% serum for 1 hour followed by treatment with DMEM 
containing 0.5% FBS or sodium orthovanadate at 1nM and 10 nM for 15 minutes. These 
concentrations were chosen based on the results obtained from the cell proliferation assays, in 
which 1 nM showed a trend to induce cell proliferation and 10 nM induced maximum 
stimulation, suggesting a range of active sodium orthovanadate concentrations. Cells were 




5.4.1 Effects of H2O2 and PDGF on protein tyrosine phosphatase activity 
I hypothesized that ROS are regulating PDGF signaling by specifically oxidizing protein 
tyrosine phosphatases, thus modulating the phosphorylation levels of kinases and other important 
enzymes. To test our hypothesis I used a protein tyrosine phosphatase assay capable of 
measuring enzymatic activity in cell lysate. The specific question I asked was whether 
exogenous hydrogen peroxide alone or PDGF treatment were able to alter protein tyrosine 
phosphatase activity in leiomyoma and myometrial cells. There was no significant effect of 
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either hydrogen peroxide or PDGF on protein tyrosine phosphatase activity in normal 
myometrial cells (Figures 28A and 29A). However, in leiomyoma cells hydrogen peroxide 
induced a significant decrease in enzymatic activity, with no effect of PDGF (Figures 28B and 
29B, respectively). Interestingly, when comparing the basal levels of protein tyrosine 
phosphatase activity in untreated leiomyoma cells versus untreated normal myometrial cells, 
leiomyoma cells appeared to have a higher basal level. 
 
5.4.2 Effects of protein tyrosine phosphatase inhibitor, sodium orthovanadate, on cell 
proliferation 
PTPases regulate signaling by dephosphorylating proteins and can therefore affect 
pathways that rely on protein phosphorylation to become activated. I know that the PDGF 
proliferative pathway, for instance, depends on auto-phosphorylation of PDGF-R to induce cell 
proliferation.  I then hypothesized that inhibition of PTPase would alter the proliferation of 
leiomyoma or myometrial cells measured by [3H]thymidine incorporation. Sodium 
orthovanadate, a broad-spectrum tyrosine phosphatase inhibitor, was used to target the enzymatic 
activity of this broad family of enzymes at a large range of concentrations. Orthovanadate had a 
biphasic effect in that at low concentrations it induced cell proliferation while higher doses had 
inhibitory effects (Figures 30A and B). Leiomyoma cells were more sensitive to the effects of 
orthovanadate than normal myometrial cells. Whereas leiomyoma cells showed increased 
proliferation at orthovanadate concentrations as low as 0.6 nM, myometrial cells were only 
induced to proliferate when treated with concentrations between 10 and 20 nM. 
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5.4.3 Effects of protein tyrosine phosphatase inhibitor, sodium orthovanadate, on PDGF-R 
phosphorylation 
Protein tyrosine phosphatases counteract the actions of kinases thereby regulating 
activation or inhibition of different proteins by post-translational modifications. Based upon the 
results indicating that hydrogen peroxide regulates the activity of tyrosine phosphatases in 
leiomyoma cells as well as the evidence for regulation of cell proliferation by a tyrosine 
phosphatase inhibitor, I assume there is a significant biological link between ROS, tyrosine 
phosphatases and the proliferative pathway in leiomyoma cells. My initial hypothesis was that 
inhibition by tyrosine phosphatases could be occurring at the level of the PDGF-R. Although it is 
reasonable to hypothesize that inhibition of tyrosine phosphatases, which counteract the auto-
phosphorylation of the PDGF-R, would allow the receptor to be more highly phosphorylated 
and/or remain phosphorylated longer, the experiments testing the effects of orthovanadate on 
basal PDGF-R phosphorylation did not show a significant effect on receptor phosphorylation 
(Figure 31).  
 
5.5 DISCUSSION 
The goal of my study was to identify potential downstream targets that may be regulated 
by ROS and also play a role in the proliferative pathways of leiomyoma and myometrial SMCs. 
The main findings of this study are that an exogenous source of ROS, hydrogen peroxide, 
inhibits the activity of PTPases in leiomyoma SMCs, and that the regulation of PTPase activity is 
important for myometrial and leiomyoma SMC proliferation. Treatment with an exogenous 
source of ROS, hydrogen peroxide, reduced PTPase activity in leiomyoma SMCs, but not in 
normal myometrial SMCs. However, treatment with PDGF had no effect on PTPase activity. 
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Regulation of PTPase by oxidation is well documented in the literature. A cysteine 
residue located at a unique position renders the enzyme susceptible to inactivation by oxidation, 
a process that is reversible [15]. Hydrogen peroxide is an oxidative molecule and has been 
implicated in several pathways as a regulator of PTPase activity [19, 143, 146]. Interestingly, 
only leiomyoma cells responded to hydrogen peroxide treatment with a decrease in PTPase 
activity in our studies. Overall the basal levels of PTPase activity were also higher in leiomyoma 
cells than in normal myometrial cells. It is possible that the levels of proteins that scavenge 
oxidative molecules are higher in myometrial cells so that the threshold of hydrogen peroxide 
levels necessary to show a significant effect on PTPase activity is higher than that of leiomyoma 
cells. According to Kappert et al. (2006) the use of antioxidants reduced hydrogen peroxide-
induced inhibition of PTPases as well as hydrogen peroxide and PDGF-induced PDGF-R 
phosphorylation [19]. Additionally, higher expression of SOD1, which scavenges hydrogen 
peroxide, protects PTPase from inactivation [181]. Higher levels of ROS scavengers in 
myometrial SMCs may protect them from both oxidative stress-related alterations and over-
activation of signaling pathways regulated by ROS. 
To test whether manipulation of PTPase activity could in fact alter cell proliferation of 
leiomyoma and myometrial SMCs, I altered my approach and used a well-characterized and 
potent broad inhibitor of PTPases, sodium orthovanadate. This approach allowed us to be sure 
that PTPases would be inhibited equally well in all cell lines even though one cell line might 
potentially have higher levels of antioxidants/ROS scavengers than another. Inhibition of 
PTPases by sodium orthovanadate caused an increase in proliferation of both cell types. 
However, leiomyoma cells responded to very low concentrations of sodium orthovanadate, 
whereas myometrial cells only responded to sodium orthovanadate concentrations that were over 
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15-fold higher. Although basal levels of PTPase activity were higher in leiomyoma cells versus 
myometrial cells as discussed in the previous paragraph, it is possible that higher levels of 
intracellular antioxidants/ROS scavengers in myometrial cells protect PTPases from oxidative-
regulated inhibition.  
My speculations that inhibition of PTPases by sodium orthovanadate would increase 
basal levels of PDGF-R phosphorylation in unstimulated cells were not confirmed. Sodium 
orthovanadate has been shown to alter protein tyrosine phosphorylation levels of signaling 
molecules in response to several factors including EGF, FGF-2, IGF-1 and PDGF [181-183]. 
Sodium orthovanadate alone or in combination with hydrogen peroxide has insulinomimetic 
activity in a mechanism that involves inhibition of PTPases and increased protein tyrosine 
phosphorylation [184]. Heffetz et al. (1990) reported that vanadate inhibited activity of extracted 
PTPases in vitro, as well as PTPase activity of intact cells in combination with hydrogen 
peroxide, but not alone. Others reported a synergistic effect of vanadate in tyrosine 
phosphorylation of signaling molecules in response to growth factors [181, 183]. The 
concentrations of vanadate used in the PDGF-R phosphorylation experiments were chosen based 
on the [3H]thymidine incorporation experiments according to concentrations that maximally 
stimulated cell proliferation. However, studies assessing the effects of vanadate on PTPase 
activity or tyrosine phosphorylation in intact cells have used concentrations that range from 2 
µM to 1 mM [125, 181, 183, 184]. According to the literature, experiments assessing the effects 
of vanadate are normally carried out by incubating vanadate with cells for 15 or 30 minutes prior 
to stimulus or by adding vanadate simultaneously with the stimulus, which does not differ from 
the approach I used in my experiments. It is possible that assessing the effects of vanadate at 
other time-points may show different results, however I believe that the major difference 
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between the results present in this study and those form other studies is due to the fact that I 
assessed the effects of vanadate alone and not in the presence of PDGF stimulation. Chiarugi et 
al. (2002) have shown increased and long-lasting PDGF-induced PDGF-R phosphorylation in the 
presence of vanadate [183]. Others showed that vanadate increased Erk1/2 phosphorylation in 
response to different factors, with a small effect of vanadate alone [125, 181]. 
In conclusion, results are suggestive of dissimilarities between leiomyoma and 
myometrial SMCs with respect to PTPase activity and its regulation. It is likely that the 
difference between the two cell types is causing the differential response to hydrogen peroxide 
and sodium orthovanadate. The exact mechanism leading to the higher or lower PTPase 
sensitivity is yet to be studied, but it certainly suggests that leiomyoma cells could have a lower 
threshold for inhibition of PTPases providing a potential growth advantage to these cells over 
normal myometrial cells. Observations from cell count experiments that MSMCs did not respond 
to hydrogen peroxide as did LSMCs (Figure 13B and APPENDIX B) support the differential 
response os these two cell types to ROS. Further characterization of the observations made in 
this study is necessary to confirm the findings and more detailed assessment of PTPase activity 













Figure 28. Regulation of protein tyrosine phosphatase activity in leiomyoma and myometrial 
SMCs. A) myometrial SMCs and B) leiomyoma SMCs were exposed to PDGF for 15 and 30 
minutes and PTPase activity was measured on cell lysate. 
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Figure 29. Regulation of protein tyrosine phosphatase activity in leiomyoma and myometrial 
SMCs. A) myometrial SMCs and B) leiomyoma SMCs were exposed to hydrogen peroxide at 10 
and 100 µM  for 15 minutes and PTPase activity was measured on cell lysate. Asterisk indicates 
that treatment is statistically different from untreated control (p<0.05). 





Figure 30. Effects of inhibition of protein tyrosine phosphatase on myometrial and leiomyoma 
SMCs. A) leiomyoma SMCs and B) myometrial SMCs were expose to different concentrations 
of sodium orthovanadate for 48 hours and rate of tritiated-thymidine incorporation was 
measured. Higher counts indicate higher cell proliferation. Different capital letters indicate 
statistical significance. 
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Figure 31. Effects of protein tyrosine phosphatase inhibition on PDGF-R phosphorylation. 
Immunoblots of phosphorylated PDGF-R (pPDGF-R) and total PDGF-R protein (tPDGF-R -  
loading control). LSMCs and MSMCs were exposed to 1 and 10 nM of sodium orthovanadate 
(VAN) for 15 minutes and cell lysate was collected for analysis. This is a representative image of 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Reactive oxygen species (ROS) play a significant role in the development of a variety of 
chronic and fibrotic disorders such as human uterine leiomyomas. The overall goal of this work 
was to investigate the mechanisms involved in the production of ROS as well as the role of ROS 
as regulators of the proliferative pathways triggered by EGF and PDGF in myometrial and 
leiomyoma SMCs. The main findings of my studies are: 1) LSMCs and MSMCs produce ROS in 
response to EGF and PDGF; 2) ROS are necessary and sufficient to induce LSMCs and MSMCs 
proliferation; 3) ROS are necessary and sufficient to induce a significant portion of Erk 
activation in LSMCs and MSMCs; 4) NADPH oxidase components are expressed in leiomyoma 
and normal myometrial tissue; 5) PDGF induces translocation of p47phox into lipid rafts in 
LSMCs; 6) PKC mediates Erk activation by PDGF in MSMCs and LSMCs; 7) PKC alone is 
sufficient to induce ROS production in MSMCs and LSMCs; 8) hydrogen peroxide inhibits the 
activity of PTPases in LSMCs; and 9) regulation of PTPase activity is important for myometrial 
and leiomyoma SMC proliferation. Based on these findings I propose a revised model to 
illustrate my working hypothesis regarding the role of ROS in the proliferative pathway of PDGF 
and EGF in LSMCs and MSMCs (Figure 32). I showed that ROS mediate, at least partially, the 
downstream signaling events of the PDGF and EGF proliferative pathways. PDGF and EGF 
trigger ROS production by activating the NADPH oxidase complex. Inhibition of ROS reduces 
the ability of PDGF to induce Erk activation, but it does not influence Erk activation in response 
to EGF. I hypothesize that ROS are necessary for the EGF proliferative pathway as evidenced by 
the ability of EGF to induce ROS production, and the decrease in EGF-induced cell proliferation 
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upon ROS inhibition. However, since this work focused mainly on the involvement of ROS in 
the activation of the Erk pathway, other pathways triggered by EGF and potentially regulated by 
ROS in leiomyoma and normal myometrial cells remain to be tested. 
Although there was no effect of PDGF treatment on the phosphorylation of the cytosolic 
NADPH oxidase subunit p47phox, the relocation of the subunit into lipid rafts upon exposure to 
PDGF may well be a significant event in NADPH oxidase complex activation and potentially in 
the PDGF signaling pathway. My data also suggest that PKC may be the kinase involved in 
activation of the NADPH oxidase complex leading to ROS production. Additionally, ROS 
reduce the activity of PTPases in LSMCs, a mechanism that leads to increased proliferation of 
MSMCs and LSMCs. 
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Figure 32 – Revised model illustrating my proposed working hypothesis of how ROS are 
involved in the proliferative pathway of PDGF in LSMCs and MSMCs. 
 The results of my studies have added to the increasingly growing body of literature that 
supports a role for ROS as signaling molecules that regulate proliferative pathways in a variety 
of cell types. While I focused on the second messenger role of controlled production of ROS, I 
cannot rule out the possibility that there may be excessive or uncontrolled production of ROS 
under certain conditions in the myometrium. Such high levels of ROS production may lead to 
oxidative stress and may potentially be responsible for the initial injury hypothesized to be 
important for the initiation of leiomyoma tumor development. This initial injury could originate 
from excessive ROS produced in response to the hypoxic conditions present in the uterus at 
menstruation. An alternative hypothesis proposes that the mechanism could also be similar to the 
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pathogenesis of atherosclerosis in which endothelial cells internalize low densisity lipoprotein 
(LDL) and, upon its accumulation, attract immune cells to phagocytize those cells, causing local 
release of large amounts of ROS. Increased local production of ROS can drive a phenotypic 
change in normally quiescent smooth muscle cells, making them myofibroblast-like cells, that 
are more proliferative and also produce large quantities of collagen. Epidemiological studies 
show an increased incidence of leiomyoms linked to obesity and hypertension that are associated 
with higher circulating levels of cholesterol. 
Additional significant findings of my studies showed, for the first time, the existence of a 
fully active and biologically significant NADPH oxidase enzyme system in normal myometrial 
and leiomyoma SMCs. Second, results also indicated the existence of a subset of leiomyoma 
tumors, within a group of 10 patients I analyzed, in which several subunit components of the 
NADPH oxidase complex were upregulated. Third, in vitro experiments suggest that although 
higher basal levels of PTPase activity were present in LSMCs, these cells also showed a higher 
sensitivity to hydrogen peroxide and PTPase inhibition compared to MSMCs. Based upon 
evidence indicating the involvement of excessive ROS production with cell transformation, as 
well as the fact that numerous cancers are associated with excessive ROS production [146, 185], 
it is likely that a growth advantage may originate from higher expression of the NADPH oxidase 
complex. In vitro culture conditions have limitations in the sense that they obviously do not 
mimic the in vivo environment, thus myometrial and leiomyoma SMCs tend to behave similarly. 
This situation is a disadvantage because potentially important differences may become subtle, 
impairing their detection. Whether the basal levels of ROS production are higher in leiomyoma 
SMCs or in the precursor cells, or whether these cells will respond more robustly to factors such 
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as PDGF commonly found at higher levels of expression in leiomyoma tumors remains to be 
determined. 
 My work in characterizing the importance of NADPH oxidase-derived ROS in the 
pathogenesis of leiomyomas is certainly just beginning. The data presented in this dissertation 
suggested a number of new questions that I would like to propose for the continuity of this 
project: 
• What are the mRNA and protein expression levels of proteins that counteract ROS, such 
as catalase, glutathione, superoxide dismutase 1, thioredoxin and glutaredoxin in normal 
myometrium versus leiomyoma tissues? 
• Does induction of PKC by PMA induce p47phox phosphorylation and translocation into 
lipid rafts? 
• Does disruption of lipid rafts by methyl-β-cyclodextrin, which enhances solubility of 
cholesterol thus extracting it from cells, affect the ability of leiomyoma or myometrial 
SMCs to produce ROS in response to PDGF? 
• Does the PTPase inhibitor sodium orthovanadate affect the extent of PDGF-R 
phosphorylation in cells treated with PDGF? 
• What specific PTPases are inhibited by ROS in myometrial and leiomyoma SMCs? 
o One potential target of these studies is PTP1B, a PTPase that has been identified 
as an important regulator of several receptor tyrosine kinase signaling pathways. 
It would be interesting to study the direct effects of ROS on PTP1B by 
immunoprecipitating the enzyme and checking its redox state by using an anti-
oxidized-PTPase antibody. Another approach would be to knockdown PTPB1 
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gene expression and test the consequences of lower or absent PTPB1 expression 
on ROS-induced cellular responses. 
• What other targets of ROS action are important for proliferative pathways in myometrial 
and leiomyoma SMCs? 
o Ras is a small G protein involved in signaling pathways of several receptor 
tyrosine kinases, and Ras mutations are involved in cell transformation. Ras-
transformed cells have increased ROS levels, and furthermore, Ras has a cysteine 
residue that is regulated by oxidation triggering enhanced nucleotide exchange. 
One could immunoprecipitate Ras protein from cells exposed to ROS and perform 
a GTPase activity assay. 
• How does an oxidized or reduced intracellular environment affect cell cycle status and 
global gene expression in myometrial and leiomyoma SMCs? 
o One could manipulate the intracellular environment by either targeting enzymes 
that scavenge ROS or counteract oxidation (e.g. catalase and thioredoxin), or 
directly target the NADPH oxidase enzymes. Gene expression knockdown of 
these enzymatic pathways, or the use of cell permeable enzymes such as catalase 
and superoxide dismutase could be tested. The latter can be achieved by using 
enzymes coupled with polyethylene glycol that allow cell permeability. Global 
gene expression can be measured by microarray analysis either through a whole 
genome screening or a targeted approach on smaller arrays focusing on specific 
pathways. Flow cytometry analysis of DNA content can be used to assess effects 
of the intracellular redox environemtnon cell cycle progression or arrest according 
to the intracellular redox environment. 
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In conclusion, leiomyoma and normal myometrial SMCs express a functional NADPH 
oxidase complex, which is the source of ROS produced in response to PDGF and EGF. NADPH 
oxidase-derived ROS are necessary for PDGF and EGF-regulated proliferation of both 
leiomyoma and myometrial SMCs. Although the Erk pathway is at least in part regulated by 
PDGF-induced ROS production, the EGF-induced ROS might regulate signaling molecules other 
than Erk involved in its proliferative pathway. Moreover, p47phox translocation into lipid rafts 
may be an important step in the PDGF signaling pathways, although p47phox phosphorylation is 
not necessary for PDGF-induced ROS production. I further conclude that PKC activity is 
necessary for ROS production in response to PDGF, and that ROS regulate protein tyrosine 
phosphatase activity, which in turn is a negative regulator of leiomyoma and normal myometrial 
SMCs proliferation. I demonstrated that ROS are necessary components of the PDGF and EGF 
signaling pathways, and showed to some extent how ROS production is triggered and how ROS 
act as second messengers to control cell proliferation. My overall findings suggest that a subset 
of tumors is composed of SMCs that overexpress NADPH oxidase components, and according to 
the current literature, overexpression of these components is correlated with increased ROS 
levels. The regulation of PTPases by ROS and the consequent effects on cell proliferation 
indicate a growth advantage of tumor cells that might explain partially the increased proliferation 
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APPENDIX A: LIST OF ABBREVIATIONS 
β-ME: beta mercaptoethanol 
ABC: Avidin:Biotynilated enzyme complex 
ACP1: acid phosphatase 1 
ANOVA: analysis of variance 
BCA: bicinchoninic acid 
BCS: bovine calf serum 
bFGF: basic fibroblast growth factor 
Bis: bisindolylmaleimide, PKC inhibitor 
BMI: body mass index 
BSA: bovine serum albumin 
CAV-1: caveolin 1 
CBP: CREB binding protein 
CDC25C: cell division cycle 25 homolog c 
CPM: counts per minute 
DAB: 3,3-Diaminobenzidine, liquid chromogen substrate kit 
DCFDA: dichlorodihydrofluorescein diacetate, oxidation sensitive dye 
DHE: dihydroethidium 
DIC-Nomarski: differential interference contrast 
DMEM: dulbecco’s modified eagle medium 
DMSO: dimethylsulphoxide 
DPBS: dulbecco’s PBS 
DPI: diphenyleneiodonium 
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DTT: dithiothreitol, reducing agent 
DUOX: dual oxidase NADPH oxidase 
ECM: extracellular matrix 
EGF: epidermal growth factor 
EGF-R: EGF receptor 
Eker rat: animal model for leiomyoma tumors 
ELT-3: leiomyom smooth muscle cell line from Eker rat 
ER: estrogen receptor 
ERK: extracellular signal regulated kinase 
FBS: fetal bovine serum 
FGF: fibroblast growth factor 
GAGs: glycosaminoglycans 
GDP: guanosine diphosphate 
GnRH: gonadotropin releasing hormone 
GTPase: GTP exchange enzyme 
H2O2: hydrogen peroxide 
HB-EGF: heparin binding epidermal growth factor 
HER-1: HB-EGF receptor 
HGF-R: hepatocyte growth factor receptor 
HRP: horseradish peroxidase 
IGF-I: insulin-like growth factor-I 
IL-1: interleukin 1 
JNK: c-jun N-terminal kinase 
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LSB: laemmli sample buffer 
LSMCS: leiomyoma SMCs 
MAPK: mitogen-activated protein kinase 
MAPK1/3: Erk1/2 
M-CSF-R: macrophage colony-stimulating factor 
MMP: matrix metalloproteinase 
MSP-R: 
NAC: n-acetyl-cysteine 
Nox: NADPH oxidase sub-unit 
Noxa1: Nox activator 1 
Noxo1: Nox organizer 1 
PBS: phosphate buffer saline 
PCNA: proliferating cell nuclear antigen 
PDGF: platelet-derived growth factor 
PDGF-R: PDGF receptor 
pEGF-R: phosphorylated EGF receptor protein 
PGF2α: prostaglandin F2 alpha 
Phox: phagocyte oxidase subunit 
PI3K: phosphatidyl inositol 3 phosphate 
PKC: protein kinase C 
PLC: phospholipase C 
PMA: phorbol 12-myristate 13-acetate 
PO4: phosphate 
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pPDGF-R: phosphorylated PDGF receptor protein 
PR: progesterone receptor 
PRF-DMEM: phenol red free DMEM 
PTEN: phosphatase and tensin homolog 
PTPase: protein tyrosine phosphatase 
PTPN1: protein tyrosine phosphatase, non receptor type 1 
qRT-PCR: real-time quantitative reverse transcription PCR 
ROS: reactive oxygen species 
RU-486: progesterone receptor antagonist 
SCF-R: stem cell factor 
SEM: standard error of the mean 
SMC: smooth muscle cells 
SM-MHC: smooth muscle-myosin heavy chain 
SRF: serum response factor 
TBS/T: tris buffer saline 
tEGF-R: total EGF receptor protein 
TGFβ1: transforming growth factor beta 1 
TIMP: tissue inhibitor of metalloproteinase 
TNFα: tumor necrosis factoa alpha 
tPDGF-R: total PDGF receptor protein 
UtSMCs: uterine SMCs (leiomyoma and myometrial SMCs) 
VEGF: vascular endothelial growth factor 
VSMCs: vascular SMCs 
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APPENDIX B: REGULATION OF CELL PROLIFERATION BY HYDROGEN PEROXIDE 
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APPENDIX C: TIME-COURSE OF ERK1/2 PHOSPHORYLATION IN RESPONSE TO EGF 
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APPENDIX D: REGULATION OF EGF- AND PDGF-INDUCED ERK1/2 
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APPENDIX F: TIME-COURSE OF ERK1/2 PHOSPHORYLATION IN RESPONSE TO 
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APPENDIX G: IMMUNOFLUORESCENCE STAINING PROTOCOL 
 
Cell Culture: 
1. Plate in 10% DMEM, no phenol red (Cells should be grown in plastic bottles (up to 90% 
confluence) in phenol red free medium washed in PR red free medium twice and 
trypsinized in PR free trypsin and transferred to wells). I feel the 4000 cell count is bit too 
much for that well size, so make it smaller but let it grow longer so that you will have 
new/fresh cells not just the cells trypsinized).  








3. Begin Fixation Procedure. 
 
Fixation: All steps at Room Temperature; 
 
- DO NOT LET SAMPLE DRY OUT!!! 
- PROCESS ONE WELL AT A TIME!!! 
o Remove medium and replace it immediately 
 
1. Wash cells in DPBS (RT) 3x with fresh DPBS each time (to remove debris and serum) 
2. Fix all cells in Paraformaldehyde (4%) in DPBS (1x) for 25 minutes at room temperature. 
a. Add 200 µl/well 
b. Make 4% PFA with 1 ml of 16% PFA and 3 ml of 1xDPBS 
c. Kept 16% PFA aliquots at 4°C. 
i. Undiluted PFA should be used within a maximum of two weeks after 
opening the vial. 
3. Wash wells 3x (5 min each) in DPBS. 
4. Permeabilize cells 
a. Incubate slides in 0.2% Triton X 100 in DPBS for 10 min 
b. Wash once in DPBS 
5. Blocking: 
a. Add signal FX to wells (be generous to cover the entire surface-250-300 
microliters) and incubate for 60 minutes 
6. Wash wells with 1x DPBS. 
7. Dilute PRIMARY Ab in DPBS/10% Signal FX or DPBS containing 0.2% BSA and 
0.05% Tween-20 
8. Centrifuge it for 5 minutes at 12,000 RPM 
a. Add supernatant to wells 
b. KEEP wells that will receive secondary antibody only in blocking buffer until it is 
time to incubate with secondary antibodies 
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9. Incubate with primary antibodies separately (one at a time on same well) at appropriate 
concentrations for 2 hours at room temperature or overnight at 4°C.  
10. Wash wells 3x (5 min each) in DPBS. 
 
(All steps from here on, keep the cell dish covered with a small box on the desk so that they 
are in the dark) 
 
11. Dilute secondary antibody in DPBS/10% FX or DPBS containing 0.2% BSA and 0.05% 
Tween-20 and centrifuge it for 5 minutes at 12,000 RPM 
a. Keep other wells on PRIMARY antibody until it is time to add secondary 
antibody; 
b. Secondary antibody used at 1:200 dilution and incubated for 1 hour; 
12. Wash all wells/dishes 3x (5 minutes each) with 1x DPBS.  
13. Incubate all wells/dishes in DAPI (5 µg/mL in 1x DPBS) for 15 minutes. 
14. Rinse all wells/dishes briefly in 1x DPBS. 
a. Make Prolong gold 10ml into 20 aliquots of 500 µl each. Store 9 of them in -20 
and leave 1 in the refrigerator. 
15. Bring Prolong Gold (in the refrigerator) to room temperature first. Then mount in Prolong 
Gold (PG). Before that make sure you drain the final DPBS as much as possible. One 
may use a kimwipe around the well area, and then add PG without trapping bubbles. Add 
to cover all cells as solution in wells will form a depression in the center of wells; 
16. Keep the dish in dark with lid loosely on top at room temp for 24 hours for prolong gold 
to cure;  























  147 
APPENDIX H: IMAGING IMMUNOFLUORESCENCE STAINED CELLS OR LIVE CELL 
DETECTION OF ROS PRODUCTION 
 
→ Turn fluorescent light ON 
 Wait 30 minutes before turning it OFF or back ON 
• Fixed cells: knob all the way up 
• Live cells: one notch up from the bottom 
→ Turn microscope ON: right side, GREEN button 
→ Turn Uniblitz (black box) ON 
→ Lambda 10-3 power button 
→ MCU28 – power button on back left side 
→ Turn computer ON 
 After logging in, type “IU” for independent use 
 Camera: MRm or MR-3 Axio (Monochrome 1388x1048 resolution) 
 Before place sample on microscope: rotate course focus towards myself until sound 
indicating objective cannot go any further is heard to bring objective down 
→ Before load the sample: 
 Polarizer has to be OUT 
 Apotome has to be OUT 
 Filter turret (DAPI-FITC-Rhodamine) has to be ON 
 For ROS production imaging, checl for the presence of the DIC cube 
→ Configuration – MTB-2004 
o Right click on IGB 
 Set active configuration – APPLY – OK 
→ Axiovision release 4.6 
→ Controls used to capture images 
 Microscope control 
• Microscope icon 
 Camera control 
• Activate camera 
o Acquisition – Select camera – MR-3 
• Acquisition – Camera – MR-3 
 Channel control 
• 6D – Acquisition 
 Live window – Live icon 
 Experiment window – File – Export 
→ To use high magnification 
→ Find focus on 5X on specific channel (DAPI for immunofluorescence, FITC for ROS 
production) 
→ Record position 
 Mark/find icon 
 Position tab 
 Blue icon to mark position once focused 
→ Move stage to the left, exposing 63X objective 
→ Add oil (small drop) 
→ Move to the recorded position 
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→ Change objective 
 Always on software 
→ Every 2 wells, go back to 5X and repeat procedure above to add new oil 
 Before adding new oil, wipe bottom of the slide with liquid, but dry lens papers for 
objectives 
 If imaging ROS production adding oil once for each dish is usually enough 
→ Load experiment 
→ Under multidimensional acquisition click on LOAD, do not use drop down menu 
→ Choose Fernando for fixed cells, and Fernando Live for ROS 
→ On experiment tab, type image name on image name field 
→ Click on “C” tab 
→ Right click on channel to disable or enable it 
→ To use DAPI 
→ Go on Hardware settings and click on GO to activate channel 
→ To turn it OFF, click on GO (off) to avoid photobleaching 
→ Go on microscope control 
→ Always start by bringing focus down, then click on 5X 
→ Before taking the shot change light path to camera SIDE PORT LEFT 
→ Now it is time to put slide ON 
→ To make sure stage is snapped in place, press down on 4 corners 
→ Bring the whole slide holder to the center, with equal space to the left and right side 
→ Use joystick to bring first well above objective 
→ Turn DAPI channel ON – GO 
→ Adjust focus and turn light OFF by clicking first top button on right side of microscope 
→ Record position 
→ Move stage to the left side to expose 63X objective 
→ Add drop of oil on objective, but not directly to lens 
 Not too much oil 
→ Click on orange button (X) on Mark/Find 
→ Then click on 63X 
 Normally needs to move objective up a little bit to adjust focus – Use fine focus 
→ Change light path to camera only 
→ Use joystick to move to different fields 
→ Check on DAPI channel to adjust focus on Live image on computer 
→ Go to camera control 
→ On Live image – select OVER EXPOSE and LINEAR 
→ Go to Frame tab and make sure resolution is maximum (1130x1088), and size is maximum 
→ Click on center 
→ Go to Adjust tab 
→ Click on DAPI 
→ Adjust exposure until a few RED dots show up, so that the whole dynamic range is covered 
→ Change adjusted exposure on DAPI channel 
 Enter value under Time 
• If 1.81s = 1810ms 
→ Click start to take shot on all channels 
→ To save picture 
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 Save as 
 My computer 
 Storage E 
 Users 
 Fernando 
 Create folder with the day’s date as the name 
 Save as ZVI format (raw data) 
→ On gallery mode, click on create image 
→ Make sure color is ON (left bottom corner) 
→ Save as 
→ Change to TIFF format 
→ Go to EXPORT window 
→ Save image 
→ Go to Fernando’s folder and select correct day’s folder 
→ Click Start 
→ Open live window again 
→ Before leaving, make sure objective 5X is in use and focus is all the way down 
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APPENDIX I: LIPID RAFT ISOLATION BY SUCROSE GRADIENT ULTRA-
CENTRIFUGATION 
 
- Cells were plated into 10 cm plastic dishes and grown up to confluence; 
- Upon reaching confluence, cells were serum-starved in DMEM-serum free for 24 hours; 
- After serum starvation, cells were treated with PDGF (10 ng/ml), EGF (50 ng/ml) or 
DMEM-serum free (Control) for 3 minutes, then cells were lysed according to the 
following procedure: 
o Taking 10 dishes at a time, remove medium of each dish and add 5 ml of ice-cold 
PBS/5mM EDTA, and place dish on ice; 
o After adding PBS/EDTA to the last dish, start scrapping cells off of the dish and 
collect cell suspension into a 50 ml conical tube; BE CAREFUL TO SCRAPE 
CELLS OFF OF THE EDGE OF THE DISHES; 
o Once cells are harvested from all dishes, centrifuge tube containing cells in 
PBS/EDTA at 1,000 RPM for 5 minutes (4°C); 
o Remove supernatant and add 500 µl of ice-cold lysis buffer to resuspend the cell 
pellet; Let cells incubate on ice for 10-15 minutes; 
 Lysis buffer 
• 0.5% TX-100 
• 25 mM Tris pH 7.4 
• 150 mM NaCl 
• 1 mM EDTA 
• 1 mM PMSF 
• 1 mM Na3VO4 
• 1 mM NaF 
• Protease inhibitor tablet 
o Add equal volume (500 µl) of ice-cold 80% Sucrose buffer to make a 40% 
Sucrose buffer + cell lysate; 
 Sucrose buffer 
• Sucrose (80%, 35%, 5%) 
• 25 mM Tris pH 7.4 
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• 150 mM NaCl 
o Keep samples on ice; 
o Take the ultracentrifuge metal parts, which will hold the plastic tubes, from the 
cold room and keep them on ice as well as the plastic tubes; 
o Insert the plastic tubes into the metal holders, always on ice; 
o Transfer a maximum of 1 ml of the 40% Sucrose/cell lysate into a ultracentrifuge 
5 ml plastic tube; 
o Very carefully and slowly load 2.5 ml of 35% Sucrose buffer; Keep the tip of the 
pipette touching the meniscus and pull the tip up as the buffer is added; Be extra 
cautious to prevent 40% and 35% buffers from mixing up; 
o Proceed similarly to add 0.5 ml of the 5% Sucrose buffer on top of the 35% layer; 
o Weight the whole set (metal holder, plastic tube with sample and metal lid) 
individually and add extra 5% Sucrose buffer to the lighter sets of samples up to 
the weight of the heaviest set so that the rotor stays balanced;  
o Remember to pre-cool ultracentrifuge to 3°C; 
o Centrifuge samples at 45,000 RPM for 12 hours at 3°C in a SW55Ti rotor, 
acceleration = max, deceleration = no brakes 
o Next day, collect fractions from top down; 
o Volume per fraction may be adjusted according to the total number of fractions 
one wants to collect; I collected 500 µl fractions for a total of 8 fractions; Leave 
the insoluble fraction in the tube; 
o Add warm (95°C) 1X LSB to the pellet and try to dissolve it by pipetting up and 
down many times; Keep warming the pellets up for 1-2 minutes and repeat the 
pipetting until the pellet is dissolved; 
o 300 µl of each fraction was combined with 100 µl of 4X LSB and denatured at 
95°C for 5 minutes; 
o Load 50 µl of each fraction into a polyacrylamide gel and freeze the left over 
lysate; 
 Gel concentration will be determined by molecular weight of target 
protein(s) 
 I used precast gel which support 50 µl of sample per well 
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• Precast gels from BioRad or PIERCE 
 I use 4-20% gradient gels because I am working with proteins that range 
from 22kDa to 190kDa 
 6 gels were run; 
o Precast gels 
 Remove comb carefully by adding water to wells and pulling it out gently 
 Use razor blade to cut and remove plastic membrane at the bottom of gel 
(demarking line) which will allow electric flow from negative to positive 
o Proceed electrophoresis and transfer as usual; 
 When setting up the transfer make sure that the bottom of the gel 
(approximately 2 mm from the bottom), which is slightly thicker than the 
rest of the gel, is removed; Otherwise, it may impair proper contact with 
the membrane; 
o After transfer, the top part of the gel including the wells will be very sticky and 
hard to remove from the membrane; Use a swab to remove gel pieces completely 
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APPENDIX J: AUTOFLUORESCENCE OF PKC INHIBITOR COMPOUNDS 
 
 
 
